1
|
Ly C, Ogana H, Kim HN, Hurwitz S, Deeds EJ, Kim YM, Rowat AC. Altered physical phenotypes of leukemia cells that survive chemotherapy treatment. Integr Biol (Camb) 2023; 15:7185561. [PMID: 37247849 DOI: 10.1093/intbio/zyad006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Revised: 04/22/2023] [Accepted: 04/29/2023] [Indexed: 05/31/2023]
Abstract
The recurrence of cancer following chemotherapy treatment is a major cause of death across solid and hematologic cancers. In B-cell acute lymphoblastic leukemia (B-ALL), relapse after initial chemotherapy treatment leads to poor patient outcomes. Here we test the hypothesis that chemotherapy-treated versus control B-ALL cells can be characterized based on cellular physical phenotypes. To quantify physical phenotypes of chemotherapy-treated leukemia cells, we use cells derived from B-ALL patients that are treated for 7 days with a standard multidrug chemotherapy regimen of vincristine, dexamethasone, and L-asparaginase (VDL). We conduct physical phenotyping of VDL-treated versus control cells by tracking the sequential deformations of single cells as they flow through a series of micron-scale constrictions in a microfluidic device; we call this method Quantitative Cyclical Deformability Cytometry. Using automated image analysis, we extract time-dependent features of deforming cells including cell size and transit time (TT) with single-cell resolution. Our findings show that VDL-treated B-ALL cells have faster TTs and transit velocity than control cells, indicating that VDL-treated cells are more deformable. We then test how effectively physical phenotypes can predict the presence of VDL-treated cells in mixed populations of VDL-treated and control cells using machine learning approaches. We find that TT measurements across a series of sequential constrictions can enhance the classification accuracy of VDL-treated cells in mixed populations using a variety of classifiers. Our findings suggest the predictive power of cell physical phenotyping as a complementary prognostic tool to detect the presence of cells that survive chemotherapy treatment. Ultimately such complementary physical phenotyping approaches could guide treatment strategies and therapeutic interventions. Insight box Cancer cells that survive chemotherapy treatment are major contributors to patient relapse, but the ability to predict recurrence remains a challenge. Here we investigate the physical properties of leukemia cells that survive treatment with chemotherapy drugs by deforming individual cells through a series of micron-scale constrictions in a microfluidic channel. Our findings reveal that leukemia cells that survive chemotherapy treatment are more deformable than control cells. We further show that machine learning algorithms applied to physical phenotyping data can predict the presence of cells that survive chemotherapy treatment in a mixed population. Such an integrated approach using physical phenotyping and machine learning could be valuable to guide patient treatments.
Collapse
Affiliation(s)
- Chau Ly
- Department of Integrative Biology & Physiology, University of California, Los Angeles, CA, USA
- Department of Bioengineering, University of California, Los Angeles, CA, USA
| | - Heather Ogana
- Department of Pediatrics, Children's Hospital Los Angeles, Division of Hematology and Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Hye Na Kim
- Department of Pediatrics, Children's Hospital Los Angeles, Division of Hematology and Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Samantha Hurwitz
- Department of Pediatrics, Children's Hospital Los Angeles, Division of Hematology and Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Eric J Deeds
- Department of Integrative Biology & Physiology, University of California, Los Angeles, CA, USA
- Institute for Quantitative and Computational Biosciences, University of California, Los Angeles, CA, USA
| | - Yong-Mi Kim
- Department of Pediatrics, Children's Hospital Los Angeles, Division of Hematology and Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Amy C Rowat
- Department of Integrative Biology & Physiology, University of California, Los Angeles, CA, USA
- Department of Bioengineering, University of California, Los Angeles, CA, USA
| |
Collapse
|
2
|
Abstract
Despite the therapeutic progress, relapse remains a major problem in the treatment of acute lymphoblastic leukemia (ALL). Most leukemia cells that survive chemotherapy are found in the bone marrow (BM), thus resistance to chemotherapy and other treatments may be partially attributed to pro-survival signaling to leukemic cells mediated by leukemia cell-microenvironment interactions. Adhesion of leukemia cells to BM stromal cells may lead to cell adhesion-mediated drug resistance (CAM-DR) mediating intracellular signaling changes that support survival of leukemia cells. In ALL and chronic lymphocytic leukemia (CLL), adhesion-mediated activation of the PI3K/AKT signaling pathway has been shown to be critical in CAM-DR. PI3K targeting inhibitors have been approved for CLL and have been evaluated preclinically in ALL. However, PI3K inhibition has yet to be approved for clinical use in ALL. Here, we review the role of PI3K signaling for normal hematopoietic and leukemia cells and summarize preclinical inhibitors of PI3K in ALL.
Collapse
Affiliation(s)
- Hye Na Kim
- Department of Pediatrics, Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, USA
| | - Heather Ogana
- Department of Pediatrics, Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, USA
| | - Vanessa Sanchez
- Department of Pediatrics, Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, USA
| | - Cydney Nichols
- Department of Pediatrics, Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, USA
| | - Yong-Mi Kim
- Department of Pediatrics, Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, USA.
| |
Collapse
|
3
|
Ruan Y, Kim HN, Ogana HA, Gang EJ, Li S, Liu HC, Bhojwani D, Wayne AS, Yang M, Kim YM. In vitro and in vivo effects of AVA4746, a novel competitive antagonist of the ligand binding of VLA-4, in B-cell acute lymphoblastic leukemia. Exp Ther Med 2021; 23:47. [PMID: 34934426 PMCID: PMC8652384 DOI: 10.3892/etm.2021.10969] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Accepted: 09/14/2021] [Indexed: 12/16/2022] Open
Abstract
Treatment of resistant or recurrent acute lymphoblastic leukemia (ALL) remains a challenge. It was previously demonstrated that the adhesion molecule integrin α4, referred to hereafter as α4, mediates the cell adhesion-mediated drug resistance (CAM-DR) of B-cell ALL by binding to vascular cell adhesion molecule-1 (VCAM-1) on bone marrow stroma. In addition, it was previously observed that the blockade of α4 with natalizumab or inhibition using the small molecule antagonist TBC3486 sensitized relapsed ALL cells to chemotherapy. However, α4-targeted therapy is not clinically available for the treatment of leukemia to date. In the present study, the use of a novel non-peptidic small molecule integrin α4 antagonist, AVA4746, as a potential new approach to combat drug-resistant B-ALL was explored. An in vitro co-culture = model of primary B-ALL cells and an in vivo xenograft model of patient-derived B-ALL cells were utilized for evaluation of AVA4746. VLA-4 conformation activation, cell adhesion/de-adhesion, endothelial tube formation, in vivo leukemia cell mobilization and survival assays were performed. AVA4746 exhibited high affinity for binding to B-ALL cells, where it also efficiently blocked ligand-binding to VCAM-1. In addition, AVA4746 caused the functional de-adhesion of primary B-ALL cells from VCAM-1. Inhibition of α4 using AVA4746 also prevented angiogenesis in vitro and when applied in combination with chemotherapy consisting of Vincristine, Dexamethasone and L-asparaginase, it prolonged the survival of ~33% of the mice in an in vivo xenograft model of B-ALL. These data implicate the potential of targeting the α4-VCAM-1 interaction using AVA4746 for the treatment of drug-resistant B-lineage ALL.
Collapse
Affiliation(s)
- Yongsheng Ruan
- Department of Pediatrics, Division of Hematology-Oncology, Children's Hospital Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA.,Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
| | - Hye Na Kim
- Department of Pediatrics, Division of Hematology-Oncology, Children's Hospital Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA
| | - Heather A Ogana
- Department of Pediatrics, Division of Hematology-Oncology, Children's Hospital Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA
| | - Eun Ji Gang
- Department of Pediatrics, Division of Hematology-Oncology, Children's Hospital Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA
| | - Shuangyue Li
- Department of Pediatrics, Division of Hematology-Oncology, Children's Hospital Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA
| | - Hsiao-Chuan Liu
- Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
| | - Deepa Bhojwani
- Department of Pediatrics, Division of Hematology-Oncology, Children's Hospital Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA
| | - Alan S Wayne
- Department of Pediatrics, Division of Hematology-Oncology, Children's Hospital Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA
| | - Mo Yang
- Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.,Research Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong 518107, P.R. China
| | - Yong-Mi Kim
- Department of Pediatrics, Division of Hematology-Oncology, Children's Hospital Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA
| |
Collapse
|
4
|
Bender Ignacio RA, Shapiro AE, Nance RM, Whitney BM, Delaney J, Bamford L, Wooten D, Karris M, Mathews WC, Kim HN, Van Rompaey SE, Keruly JC, Burkholder G, Napravnik S, Mayer KH, Jacobson J, Saag MS, Moore RD, Eron JJ, Willig AL, Christopoulos KA, Martin J, Hunt PW, Crane HM, Kitahata MM, Cachay E. Racial and ethnic disparities in COVID-19 disease incidence independent of comorbidities, among people with HIV in the US. medRxiv 2021:2021.12.07.21267296. [PMID: 34909782 PMCID: PMC8669849 DOI: 10.1101/2021.12.07.21267296] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVES To define the incidence of clinically-detected COVID-19 in people with HIV (PWH) in the US and evaluate how racial and ethnic disparities, comorbidities, and HIV-related factors contribute to risk of COVID-19. DESIGN Observational study within the CFAR Network of Integrated Clinical Systems cohort in 7 cities during 2020. METHODS We calculated cumulative incidence rates of COVID-19 diagnosis among PWH in routine care by key characteristics including race/ethnicity, current and lowest CD4 count, and geographic area. We evaluated risk factors for COVID-19 among PWH using relative risk regression models adjusted with disease risk scores. RESULTS Among 16,056 PWH in care, of whom 44.5% were Black, 12.5% were Hispanic, with a median age of 52 years (IQR 40-59), 18% had a current CD4 count < 350, including 7% < 200; 95.5% were on antiretroviral therapy, and 85.6% were virologically suppressed. Overall in 2020, 649 PWH were diagnosed with COVID-19 for a rate of 4.94 cases per 100 person-years. The cumulative incidence of COVID-19 was 2.4-fold and 1.7-fold higher in Hispanic and Black PWH respectively, than non-Hispanic White PWH. In adjusted analyses, factors associated with COVID-19 included female sex, Hispanic or Black identity, lowest historical CD4 count <350 (proxy for CD4 nadir), current low CD4/CD8 ratio, diabetes, and obesity. CONCLUSIONS Our results suggest that the presence of structural racial inequities above and beyond medical comorbidities increased the risk of COVID-19 among PWHPWH with immune exhaustion as evidenced by lowest historical CD4 or current low CD4:CD8 ratio had greater risk of COVID-19.
Collapse
Affiliation(s)
- R A Bender Ignacio
- University of Washington, Seattle, WA, USA
- Fred Hutchinson Cancer Research Center
| | - A E Shapiro
- University of Washington, Seattle, WA, USA
- Fred Hutchinson Cancer Research Center
| | - R M Nance
- University of Washington, Seattle, WA, USA
| | | | | | - L Bamford
- University of California San Diego, San Diego, CA, USA
| | - D Wooten
- University of California San Diego, San Diego, CA, USA
| | - M Karris
- University of California San Diego, San Diego, CA, USA
| | - W C Mathews
- University of California San Diego, San Diego, CA, USA
| | - H N Kim
- University of Washington, Seattle, WA, USA
| | | | - J C Keruly
- Johns Hopkins School of Medicine, Baltimore, MD
| | - G Burkholder
- University of Alabama at Birmingham, Birmingham, AL, USA
| | - S Napravnik
- University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - K H Mayer
- Fenway Health and Harvard Medical School, Boston, MA, USA
| | - J Jacobson
- Case Western Reserve University, Cleveland, OH, USA
| | - M S Saag
- University of Alabama at Birmingham, Birmingham, AL, USA
| | - R D Moore
- Johns Hopkins School of Medicine, Baltimore, MD
| | - J J Eron
- University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - A L Willig
- University of Alabama at Birmingham, Birmingham, AL, USA
| | | | - J Martin
- University of California, San Francisco, San Francisco, CA, USA
| | - P W Hunt
- University of California, San Francisco, San Francisco, CA, USA
| | - H M Crane
- University of Washington, Seattle, WA, USA
| | | | - E Cachay
- University of California San Diego, San Diego, CA, USA
| |
Collapse
|
5
|
Ruan Y, Kim HN, Ogana HA, Wan Z, Hurwitz S, Nichols C, Abdel-Azim N, Coba A, Seo S, Loh YHE, Gang EJ, Abdel-Azim H, Hsieh CL, Lieber MR, Parekh C, Pal D, Bhojwani D, Durden DL, Kim YM. Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia. Front Oncol 2021; 11:766888. [PMID: 34926269 PMCID: PMC8671162 DOI: 10.3389/fonc.2021.766888] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Accepted: 11/11/2021] [Indexed: 12/20/2022] Open
Abstract
The PI3K/Akt pathway—and in particular PI3Kδ—is known for its role in drug resistant B-cell acute lymphoblastic leukemia (B-ALL) and it is often upregulated in refractory or relapsed B-ALL. Myc proteins are transcription factors responsible for transcribing pro-proliferative genes and c-Myc is often overexpressed in cancers. The chromatin regulator BRD4 is required for expression of c-Myc in hematologic malignancies including B-ALL. Previously, combination of BRD4 and PI3K inhibition with SF2523 was shown to successfully decrease Myc expression. However, the underlying mechanism and effect of dual inhibition of PI3Kδ/BRD4 in B-ALL remains unknown. To study this, we utilized SF2535, a novel small molecule dual inhibitor which can specifically target the PI3Kδ isoform and BRD4. We treated primary B-ALL cells with various concentrations of SF2535 and studied its effect on specific pharmacological on-target mechanisms such as apoptosis, cell cycle, cell proliferation, and adhesion molecules expression usingin vitro and in vivo models. SF2535 significantly downregulates both c-Myc mRNA and protein expression through inhibition of BRD4 at the c-Myc promoter site and decreases p-AKT expression through inhibition of the PI3Kδ/AKT pathway. SF2535 induced apoptosis in B-ALL by downregulation of BCL-2 and increased cleavage of caspase-3, caspase-7, and PARP. Moreover, SF2535 induced cell cycle arrest and decreased cell counts in B-ALL. Interestingly, SF2535 decreased the mean fluorescence intensity (MFI) of integrin α4, α5, α6, and β1 while increasing MFI of CXCR4, indicating that SF2535 may work through inside-out signaling of integrins. Taken together, our data provide a rationale for the clinical evaluation of targeting PI3Kδ/BRD4 in refractory or relapsed B-ALL using SF2535.
Collapse
Affiliation(s)
- Yongsheng Ruan
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
- Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Hye Na Kim
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
| | - Heather A. Ogana
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
| | - Zesheng Wan
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
| | - Samantha Hurwitz
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
| | - Cydney Nichols
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
| | - Nour Abdel-Azim
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
| | - Ariana Coba
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
| | - Seyoung Seo
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
| | - Yong-Hwee Eddie Loh
- University of Southern California (USC) Libraries Bioinformatics Services, University of Southern California, Los Angeles, CA, United States
| | - Eun Ji Gang
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
| | - Hisham Abdel-Azim
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
| | - Chih-Lin Hsieh
- University of Southern California (USC) Department of Urology, University of Southern California (USC) Norris Comprehensive Cancer Center, Los Angeles, CA, United States
| | - Michael R. Lieber
- University of Southern California (USC) Department of Pathology, University of Southern California (USC) Norris Comprehensive Cancer Center, Los Angeles, CA, United States
| | - Chintan Parekh
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
| | - Dhananjaya Pal
- Department of Pediatrics, University of California San Diego, San Diego, CA, United States
| | - Deepa Bhojwani
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
| | - Donald L. Durden
- Department of Pediatrics, University of California San Diego, San Diego, CA, United States
- SignalRx Pharmaceuticals Inc., Omaha, NE, United States
| | - Yong-Mi Kim
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
- *Correspondence: Yong-Mi Kim,
| |
Collapse
|
6
|
Schönthal AH, Swenson S, Minea RO, Kim HN, Cho H, Mohseni N, Kim YM, Chen TC. Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia. Cancers (Basel) 2021; 13:cancers13143385. [PMID: 34298603 PMCID: PMC8305595 DOI: 10.3390/cancers13143385] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2021] [Revised: 07/01/2021] [Accepted: 07/04/2021] [Indexed: 12/29/2022] Open
Abstract
Simple Summary Many patients are still dying from acute myeloid leukemia (AML). Initial treatment of this blood-borne cancer consists of chemotherapy, usually with the agent cytarabine (AraC). However, the cancer cells can become drug resistant and unresponsive to AraC, which complicates further treatment and worsens prognosis. More effective treatments are needed. We are developing a novel anticancer compound called NEO212. We investigated its AML-therapeutic potential with the use of AraC-resistant AML cells grown in culture and in mice implanted with such AML cells. We found that NEO212 effectively killed AML cells in culture. The majority of AML mice that received NEO212 treatment survived and thrived without signs of tumor recurrence. At the same time, NEO212 treatment did not result in any detectable side effects, showing that this drug was very well tolerated by these animals. We deem it worthwhile to further develop NEO212 toward its evaluation in AML patients, in particular in those where initial therapy with AraC has failed. Abstract Despite progress in the treatment of acute myeloid leukemia (AML), the clinical outcome remains suboptimal and many patients are still dying from this disease. First-line treatment consists of chemotherapy, which typically includes cytarabine (AraC), either alone or in combination with anthracyclines, but drug resistance can develop and significantly worsen prognosis. Better treatments are needed. We are developing a novel anticancer compound, NEO212, that was created by covalent conjugation of two different molecules with already established anticancer activity, the alkylating agent temozolomide (TMZ) and the natural monoterpene perillyl alcohol (POH). We investigated the anticancer activity of NEO212 in several in vitro and in vivo models of AML. Human HL60 and U937 AML cell lines, as well as different AraC-resistant AML cell lines, were treated with NEO212 and effects on cell proliferation, cell cycle, and cell death were investigated. Mice with implanted AraC-sensitive or AraC-resistant AML cells were dosed with oral NEO212, and animal survival was monitored. Our in vitro experiments show that treatment of cells with NEO212 results in growth inhibition via potent G2 arrest, which is followed by apoptotic cell death. Intriguingly, NEO212 was equally potent in highly AraC-resistant cells. In vivo, NEO212 treatment strikingly extended survival of AML mice and the majority of treated mice continued to thrive and survive without any signs of illness. At the same time, we were unable to detect toxic side effects of NEO212 treatment. All in all, the absence of side effects, combined with striking therapeutic activity even in an AraC-resistant context, suggests that NEO212 should be developed further toward clinical testing.
Collapse
Affiliation(s)
- Axel H. Schönthal
- Department of Molecular Microbiology & Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA;
- Correspondence: (A.H.S.); (T.C.C.); Tel.: +1-323-442-1730 (A.H.S.); +1-323-409-7422 (T.C.C.); Fax: +1-323-442-1721 (A.H.S.); +1-323-226-7833 (T.C.C.)
| | - Steve Swenson
- Department of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA; (S.S.); (R.O.M.); (H.C.)
| | - Radu O. Minea
- Department of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA; (S.S.); (R.O.M.); (H.C.)
| | - Hye Na Kim
- Department Pediatrics, Division of Hematology, Oncology, Blood and Bone Marrow Transplantation, Children’s Hospital of Los Angeles, Los Angeles, CA 90027, USA; (H.N.K.); (Y.-M.K.)
| | - Heeyeon Cho
- Department of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA; (S.S.); (R.O.M.); (H.C.)
| | - Nazleen Mohseni
- Department of Molecular Microbiology & Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA;
| | - Yong-Mi Kim
- Department Pediatrics, Division of Hematology, Oncology, Blood and Bone Marrow Transplantation, Children’s Hospital of Los Angeles, Los Angeles, CA 90027, USA; (H.N.K.); (Y.-M.K.)
| | - Thomas C. Chen
- Department of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA; (S.S.); (R.O.M.); (H.C.)
- Correspondence: (A.H.S.); (T.C.C.); Tel.: +1-323-442-1730 (A.H.S.); +1-323-409-7422 (T.C.C.); Fax: +1-323-442-1721 (A.H.S.); +1-323-226-7833 (T.C.C.)
| |
Collapse
|
7
|
Abstract
Dysregulated Wnt signaling plays a central role in initiation, progression, and metastasis in many types of human cancers. Cancer development and resistance to conventional cancer therapies are highly associated with the tumor microenvironment (TME), which is composed of numerous stable non-cancer cells, including immune cells, extracellular matrix (ECM), fibroblasts, endothelial cells (ECs), and stromal cells. Recently, increasing evidence suggests that the relationship between Wnt signaling and the TME promotes the proliferation and maintenance of tumor cells, including leukemia. Here, we review the Wnt pathway, the role of Wnt signaling in different components of the TME, and therapeutic strategies for targeting Wnt signaling.
Collapse
Affiliation(s)
- Yongsheng Ruan
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, USA.,Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Heather Ogana
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, USA
| | - Eunji Gang
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, USA
| | - Hye Na Kim
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, USA
| | - Yong-Mi Kim
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, USA.
| |
Collapse
|
8
|
Abstract
The interaction between leukemia cells and the bone microenvironment is known to provide drug resistance in leukemia cells. This phenomenon, called cell adhesion-mediated drug resistance (CAM-DR), has been demonstrated in many subsets of leukemia including B- and T-acute lymphoblastic leukemia (B- and T-ALL) and acute myeloid leukemia (AML). Cell adhesion molecules (CAMs) are surface molecules that allow cell-cell or cell-extracellular matrix (ECM) adhesion. CAMs not only recognize ligands for binding but also initiate the intracellular signaling pathways that are associated with cell proliferation, survival, and drug resistance upon binding to their ligands. Cadherins, selectins, and integrins are well-known cell adhesion molecules that allow binding to neighboring cells, ECM proteins, and soluble factors. The expression of cadherin, selectin, and integrin correlates with the increased drug resistance of leukemia cells. This paper will review the role of cadherins, selectins, and integrins in CAM-DR and the results of clinical trials targeting these molecules.
Collapse
Affiliation(s)
- Hye Na Kim
- Children's Hospital Los Angeles, Keck School of Medicine of University of Southern California, Cancer and Blood Disease Institute, Los Angeles, CA, United States
| | - Yongsheng Ruan
- Children's Hospital Los Angeles, Keck School of Medicine of University of Southern California, Cancer and Blood Disease Institute, Los Angeles, CA, United States.,Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Heather Ogana
- Children's Hospital Los Angeles, Keck School of Medicine of University of Southern California, Cancer and Blood Disease Institute, Los Angeles, CA, United States
| | - Yong-Mi Kim
- Children's Hospital Los Angeles, Keck School of Medicine of University of Southern California, Cancer and Blood Disease Institute, Los Angeles, CA, United States
| |
Collapse
|
9
|
Ruan Y, Kim HN, Ogana H, Kim YM. Wnt Signaling in Leukemia and Its Bone Marrow Microenvironment. Int J Mol Sci 2020; 21:ijms21176247. [PMID: 32872365 PMCID: PMC7503842 DOI: 10.3390/ijms21176247] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Revised: 08/16/2020] [Accepted: 08/24/2020] [Indexed: 12/19/2022] Open
Abstract
Leukemia is an aggressive hematologic neoplastic disease. Therapy-resistant leukemic stem cells (LSCs) may contribute to the relapse of the disease. LSCs are thought to be protected in the leukemia microenvironment, mainly consisting of mesenchymal stem/stromal cells (MSC), endothelial cells, and osteoblasts. Canonical and noncanonical Wnt pathways play a critical role in the maintenance of normal hematopoietic stem cells (HSC) and LSCs. In this review, we summarize recent findings on the role of Wnt signaling in leukemia and its microenvironment and provide information on the currently available strategies for targeting Wnt signaling.
Collapse
Affiliation(s)
- Yongsheng Ruan
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90027, USA; (Y.R.); (H.N.K.); (H.O.)
- Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - Hye Na Kim
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90027, USA; (Y.R.); (H.N.K.); (H.O.)
| | - Heather Ogana
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90027, USA; (Y.R.); (H.N.K.); (H.O.)
| | - Yong-Mi Kim
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90027, USA; (Y.R.); (H.N.K.); (H.O.)
- Correspondence:
| |
Collapse
|
10
|
Liu HC, Gang EJ, Kim HN, Ruan Y, Ogana H, Wan Z, Bönig H, Shung KK, Kim YM. Characterizing the Motility of Chemotherapeutics-Treated Acute Lymphoblastic Leukemia Cells by Time-Lapse Imaging. Cells 2020; 9:E1470. [PMID: 32560076 PMCID: PMC7349263 DOI: 10.3390/cells9061470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Revised: 06/11/2020] [Accepted: 06/11/2020] [Indexed: 11/16/2022] Open
Abstract
Drug resistance is an obstacle in the therapy of acute lymphoblastic leukemia (ALL). Whether the physical properties such as the motility of the cells contribute to the survival of ALL cells after drug treatment has recently been of increasing interest, as they could potentially allow the metastasis of solid tumor cells and the migration of leukemia cells. We hypothesized that chemotherapeutic treatment may alter these physical cellular properties. To investigate the motility of chemotherapeutics-treated B-cell ALL (B-ALL) cells, patient-derived B-ALL cells were treated with chemotherapy for 7 days and left for 12 h without chemotherapeutic treatment. Two parameters of motility were studied, velocity and migration distance, using a time-lapse imaging system. The study revealed that compared to non-chemotherapeutically treated B-ALL cells, B-ALL cells that survived chemotherapy treatment after 7 days showed reduced motility. We had previously shown that Tysabri and P5G10, antibodies against the adhesion molecules integrins α4 and α6, respectively, may overcome drug resistance mediated through leukemia cell adhesion to bone marrow stromal cells. Therefore, we tested the effect of integrin α4 or α6 blockade on the motility of chemotherapeutics-treated ALL cells. Only integrin α4 blockade decreased the motility and velocity of two chemotherapeutics-treated ALL cell lines. Interestingly, integrin α6 blockade did not affect the velocity of chemoresistant ALL cells. This study explores the physical properties of the movements of chemoresistant B-ALL cells and highlights a potential link to integrins. Further studies to investigate the underlying mechanism are warranted.
Collapse
Affiliation(s)
- Hsiao-Chuan Liu
- Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA;
| | - Eun Ji Gang
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, University of Southern California, Los Angeles, CA 90027, USA; (E.J.G.); (H.N.K.); (Y.R.); (H.O.); (Z.W.)
| | - Hye Na Kim
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, University of Southern California, Los Angeles, CA 90027, USA; (E.J.G.); (H.N.K.); (Y.R.); (H.O.); (Z.W.)
| | - Yongsheng Ruan
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, University of Southern California, Los Angeles, CA 90027, USA; (E.J.G.); (H.N.K.); (Y.R.); (H.O.); (Z.W.)
| | - Heather Ogana
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, University of Southern California, Los Angeles, CA 90027, USA; (E.J.G.); (H.N.K.); (Y.R.); (H.O.); (Z.W.)
| | - Zesheng Wan
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, University of Southern California, Los Angeles, CA 90027, USA; (E.J.G.); (H.N.K.); (Y.R.); (H.O.); (Z.W.)
| | - Halvard Bönig
- Goethe University School of Medicine, Institute for Transfusion Medicine and Immunohematology and German Red Cross Blood Service BaWuHe, 60528 Frankfurt, Germany;
- Division of Hematology, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98198, USA
| | - K. Kirk Shung
- Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA;
| | - Yong-Mi Kim
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children’s Hospital Los Angeles, University of Southern California, Los Angeles, CA 90027, USA; (E.J.G.); (H.N.K.); (Y.R.); (H.O.); (Z.W.)
| |
Collapse
|
11
|
Fousek K, Watanabe J, Joseph SK, George A, An X, Byrd TT, Morris JS, Luong A, Martínez-Paniagua MA, Sanber K, Navai SA, Gad AZ, Salsman VS, Mathew PR, Kim HN, Wagner DL, Brunetti L, Jang A, Baker ML, Varadarajan N, Hegde M, Kim YM, Heisterkamp N, Abdel-Azim H, Ahmed N. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia 2020; 35:75-89. [PMID: 32205861 PMCID: PMC7519582 DOI: 10.1038/s41375-020-0792-2] [Citation(s) in RCA: 93] [Impact Index Per Article: 23.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Revised: 02/23/2020] [Accepted: 02/28/2020] [Indexed: 12/26/2022]
Abstract
Chimeric antigen receptor (CAR) T-cells targeting CD19 demonstrate remarkable efficacy in treating B-lineage acute lymphoblastic leukemia (BL-ALL), yet up to 39% of treated patients relapse with CD19(−) disease. We report that CD19(−) escape is associated with downregulation, but preservation, of targetable expression of CD20 and CD22. Accordingly, we reasoned that broadening the spectrum of CD19CAR T-cells to include both CD20 and CD22 would enable them to target CD19(−) escape BL-ALL while preserving their upfront efficacy. We created a CD19/20/22-targeting CAR T-cell by coexpressing individual CAR molecules on a single T-cell using one tricistronic transgene. CD19/20/22CAR T-cells killed CD19(−) blasts from patients who relapsed after CD19CAR T-cell therapy and CRISPR/Cas9 CD19 knockout primary BL-ALL both in vitro and in an animal model, while CD19CAR T-cells were ineffective. At the subcellular level, CD19/20/22CAR T-cells formed dense immune synapses with target cells that mediated effective cytolytic complex formation, were efficient serial killers in single-cell tracking studies, and were as efficacious as CD19CAR T-cells against primary CD19(+) disease. In conclusion, independent of CD19 expression, CD19/20/22CAR T-cells could be used as salvage or front-line CAR therapy for patients with recalcitrant disease.
Collapse
Affiliation(s)
- Kristen Fousek
- Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA.,Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.,Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.,Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - Junji Watanabe
- Division of Hematology, Oncology and Bone Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, CA, United States
| | - Sujith K Joseph
- Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.,Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.,Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - Ann George
- Division of Hematology, Oncology and Bone Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, CA, United States
| | - Xingyue An
- Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA
| | - Tiara T Byrd
- Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA.,Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.,Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.,Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - Jessica S Morris
- Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA.,Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.,Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.,Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - Annie Luong
- Division of Hematology, Oncology and Bone Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, CA, United States.,University of Southern California Keck School of Medicine, Los Angeles, CA, USA
| | | | - Khaled Sanber
- Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.,Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.,Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - Shoba A Navai
- Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.,Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.,Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - Ahmed Z Gad
- Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA.,Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.,Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.,Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - Vita S Salsman
- Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.,Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.,Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - Pretty R Mathew
- Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.,Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.,Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - Hye Na Kim
- Division of Hematology, Oncology and Bone Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, CA, United States.,University of Southern California Keck School of Medicine, Los Angeles, CA, USA
| | - Dimitrios L Wagner
- Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.,Institute of Medical Immunology, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany.,Berlin Institute of Health-Center for Regenerative Therapies (B-CRT), Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Lorenzo Brunetti
- Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA
| | - Albert Jang
- Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA
| | - Matthew L Baker
- National Center for Macromolecular Imaging and Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX, USA
| | - Navin Varadarajan
- Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA
| | - Meenakshi Hegde
- Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.,Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.,Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - Yong-Mi Kim
- Division of Hematology, Oncology and Bone Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, CA, United States.,University of Southern California Keck School of Medicine, Los Angeles, CA, USA
| | - Nora Heisterkamp
- Division of Hematology, Oncology and Bone Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, CA, United States.,University of Southern California Keck School of Medicine, Los Angeles, CA, USA.,Department of Systems Biology, Beckman Research Institute City of Hope, Duarte, CA, United States
| | - Hisham Abdel-Azim
- Division of Hematology, Oncology and Bone Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, CA, United States. .,University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
| | - Nabil Ahmed
- Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA. .,Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA. .,Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. .,Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
| |
Collapse
|
12
|
Liu HC, Gang EJ, Kim HN, Abdel-Azim N, Chen R, Abdel-Azim H, Shung KK, Kim YM. Integrin Antibody Decreases Deformability of Patient-Derived Pre-B Acute Lymphocytic Leukemia Cells as Measured by High-Frequency Acoustic Tweezers. J Ultrasound Med 2020; 39:589-595. [PMID: 31633840 PMCID: PMC7493593 DOI: 10.1002/jum.15139] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/04/2019] [Accepted: 09/03/2019] [Indexed: 05/11/2023]
Abstract
OBJECTIVES This article reports a study of cell mechanics in patient-derived (primary) B-cell acute lymphocytic leukemia (ALL) cells treated with antibodies against integrins. Leukemia cell adhesion to stromal cells mediates chemotherapeutic drug resistance, also known as cell adhesion-mediated chemotherapeutic drug resistance. We have previously shown that antibodies against integrin α4 and α6 adhesion molecules can de-adhere ALL cells from stromal cells or counter-receptors. Because drug-resistant cells are more deformable, as evaluated by single-beam acoustic tweezers, we hypothesized that changes in cell mechanics might contribute to the de-adhesive effect of integrin-targeting antibodies. METHODS In this study, the deformability of primary pre-B ALL cells was evaluated by single-beam acoustic tweezers after treatments with the de-adhering antibody Tysabri or P5G10 against integrin α4 and α6 adhesion molecules. RESULTS We demonstrated that primary ALL cells treated with P5G10 expressed decreased deformability compared with immunoglobulin G1 -treated control cells (P < .05). Tysabri did not show an effect on deformability (P > .05). CONCLUSIONS These results suggest that decreased deformability is associated with an integrin α6 blockade. Further assessments of the functional roles of deformability and integrin blockades in B-ALL cell drug resistance and deformability, respectively, are necessary.
Collapse
Affiliation(s)
- Hsiao-Chuan Liu
- Department of Biomedical Engineering and National Institutes of Health Ultrasonic Transducer Resource Center, University of Southern California, Los Angeles, California, USA
- Department of Pediatrics, Division of Hematology, Oncology, Blood, and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, USA
| | - Eun Ji Gang
- Department of Pediatrics, Division of Hematology, Oncology, Blood, and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, USA
| | - Hye Na Kim
- Department of Pediatrics, Division of Hematology, Oncology, Blood, and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, USA
| | - Nour Abdel-Azim
- Department of Pediatrics, Division of Hematology, Oncology, Blood, and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, USA
| | - Ruimin Chen
- Department of Biomedical Engineering and National Institutes of Health Ultrasonic Transducer Resource Center, University of Southern California, Los Angeles, California, USA
| | - Hisham Abdel-Azim
- Department of Pediatrics, Division of Hematology, Oncology, Blood, and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, USA
| | - K Kirk Shung
- Department of Pediatrics, Division of Hematology, Oncology, Blood, and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, USA
| | - Yong-Mi Kim
- Department of Pediatrics, Division of Hematology, Oncology, Blood, and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California, USA
| |
Collapse
|
13
|
Kruse A, Abdel-Azim N, Kim HN, Ruan Y, Phan V, Ogana H, Wang W, Lee R, Gang EJ, Khazal S, Kim YM. Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia. Int J Mol Sci 2020; 21:ijms21031054. [PMID: 32033444 PMCID: PMC7037356 DOI: 10.3390/ijms21031054] [Citation(s) in RCA: 53] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Revised: 01/30/2020] [Accepted: 02/03/2020] [Indexed: 02/04/2023] Open
Abstract
Minimal residual disease (MRD) refers to a chemotherapy/radiotherapy-surviving leukemia cell population that gives rise to relapse of the disease. The detection of MRD is critical for predicting the outcome and for selecting the intensity of further treatment strategies. The development of various new diagnostic platforms, including next-generation sequencing (NGS), has introduced significant advances in the sensitivity of MRD diagnostics. Here, we review current methods to diagnose MRD through phenotypic marker patterns or differential gene patterns through analysis by flow cytometry (FCM), polymerase chain reaction (PCR), real-time quantitative polymerase chain reaction (RQ-PCR), reverse transcription polymerase chain reaction (RT-PCR) or NGS. Future advances in clinical procedures will be molded by practical feasibility and patient needs regarding greater diagnostic sensitivity.
Collapse
Affiliation(s)
- Aaron Kruse
- Children’s Hospital Los Angeles, University of Southern California, 4650 Sunset Boulevard, MS #57, Los Angeles, CA 90027, USA; (A.K.); (N.A.-A.); (H.N.K.); (Y.R.); (V.P.); (H.O.); (W.W.); (R.L.); (E.J.G.)
| | - Nour Abdel-Azim
- Children’s Hospital Los Angeles, University of Southern California, 4650 Sunset Boulevard, MS #57, Los Angeles, CA 90027, USA; (A.K.); (N.A.-A.); (H.N.K.); (Y.R.); (V.P.); (H.O.); (W.W.); (R.L.); (E.J.G.)
| | - Hye Na Kim
- Children’s Hospital Los Angeles, University of Southern California, 4650 Sunset Boulevard, MS #57, Los Angeles, CA 90027, USA; (A.K.); (N.A.-A.); (H.N.K.); (Y.R.); (V.P.); (H.O.); (W.W.); (R.L.); (E.J.G.)
| | - Yongsheng Ruan
- Children’s Hospital Los Angeles, University of Southern California, 4650 Sunset Boulevard, MS #57, Los Angeles, CA 90027, USA; (A.K.); (N.A.-A.); (H.N.K.); (Y.R.); (V.P.); (H.O.); (W.W.); (R.L.); (E.J.G.)
| | - Valerie Phan
- Children’s Hospital Los Angeles, University of Southern California, 4650 Sunset Boulevard, MS #57, Los Angeles, CA 90027, USA; (A.K.); (N.A.-A.); (H.N.K.); (Y.R.); (V.P.); (H.O.); (W.W.); (R.L.); (E.J.G.)
| | - Heather Ogana
- Children’s Hospital Los Angeles, University of Southern California, 4650 Sunset Boulevard, MS #57, Los Angeles, CA 90027, USA; (A.K.); (N.A.-A.); (H.N.K.); (Y.R.); (V.P.); (H.O.); (W.W.); (R.L.); (E.J.G.)
| | - William Wang
- Children’s Hospital Los Angeles, University of Southern California, 4650 Sunset Boulevard, MS #57, Los Angeles, CA 90027, USA; (A.K.); (N.A.-A.); (H.N.K.); (Y.R.); (V.P.); (H.O.); (W.W.); (R.L.); (E.J.G.)
| | - Rachel Lee
- Children’s Hospital Los Angeles, University of Southern California, 4650 Sunset Boulevard, MS #57, Los Angeles, CA 90027, USA; (A.K.); (N.A.-A.); (H.N.K.); (Y.R.); (V.P.); (H.O.); (W.W.); (R.L.); (E.J.G.)
| | - Eun Ji Gang
- Children’s Hospital Los Angeles, University of Southern California, 4650 Sunset Boulevard, MS #57, Los Angeles, CA 90027, USA; (A.K.); (N.A.-A.); (H.N.K.); (Y.R.); (V.P.); (H.O.); (W.W.); (R.L.); (E.J.G.)
| | - Sajad Khazal
- Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA;
| | - Yong-Mi Kim
- Children’s Hospital Los Angeles, University of Southern California, 4650 Sunset Boulevard, MS #57, Los Angeles, CA 90027, USA; (A.K.); (N.A.-A.); (H.N.K.); (Y.R.); (V.P.); (H.O.); (W.W.); (R.L.); (E.J.G.)
- Correspondence:
| |
Collapse
|
14
|
Park YJ, Lee JH, Park BE, Kim HN, Jang SY, Bae MH, Yang DH, Park HS, Cho Y, Chae SC. P3617Systolic blood pressure, glycemic control and clinical outcome in diabetic patients with acute myocardial infarction. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Recent blood pressure guidelines recommend intensive blood pressure control in diabetic patients with cardiovascular disease.
Purpose
We sought to investigate combined impact of intensive blood glucose lowering and blood pressure control on clinical outcome in diabetic patients with acute myocardial infarction (AMI) has not been fully investigated yet.
Method
Korean Acute Myocardial Infarction Registry (KAMIR) – National Institute of Health (NIH) database included 12,179 patients (9,046 men; mean age = 63.6±12.6 year-old) who were discharged alive. Among them, 3,430 (28.2%) had a diabetes mellitus (DM). MACCEs were defined as a composition of all cause death, non-fatal MI, repeat revascularizations including repeated percutaneous coronary intervention and coronary bypass grafting, cerebrovascular accident and rehospitalizations at 1 year. This research was supported by a fund by Research of Korea Centers for Disease Control and Prevention.
Result
We determined cut-off value of discharge systolic blood pressure (SBP) to predict 1-year MACCE in DM and non-DM patients. Discharge SBP of less than 130mmHg was associated with a lower MACCE at 1 year compared to SBP level of 130mmHg or greater (10.8% versus 15.4%; log-rank p=0.001) in DM patients, whereas discharge SBP cut-off level was 140mmHg to discriminate 1-year MACCE in non-DM patients (6.4% versus 8.5%, log-rank p=0.045). In DM patients, there were no significant difference in 1-year MACCEs between patients with HbA1c less than 7% versus 7% or greater (12.0% versus 10.7%; log-rank p=0.325). DM patients were categorized into 4 groups; discharge SBP <130mmHg and HbA1c <7% (Group 1); discharge SBP <130mmHg and HbA1c ≥7% (Group 2); discharge SBP ≥130mmHg and HbA1c <7% (Group 3); discharge SBP ≥130mmHg and HbA1c ≥7% (Group 4). Intensive BP control was associated lower 1-year MACCEs in patients with good glycemic control (Group 1 & 3; 10.7% versus 16.7%; log-rank p=0.009). However, in patients with poor glycemic control, intensive BP control did not improve 1-year MACCEs (Group 2 & 4; 10.6% versus 11.1%; log-rank p=0.761).
Conclusion
Strict BP control is more important than glycemic control to improve short-term clinical outcome in DM patients with AMI. However, in patients with poor glycemic control, strict BP control did not improve clinical outcome.
Collapse
Affiliation(s)
- Y J Park
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| | - J H Lee
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| | - B E Park
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| | - H N Kim
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| | - S Y Jang
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| | - M H Bae
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| | - D H Yang
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| | - H S Park
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| | - Y Cho
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| | - S C Chae
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| |
Collapse
|
15
|
Park YJ, Lee JH, Park BE, Kim HN, Jang SY, Bae MH, Yang DH, Park HS, Cho Y, Chae SC. P3583Optimal procedural strategy to improve clinical outcome in primary percutaneous coronary intervention. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Current guideline recommends potent antiplatelet agents and transradial intervention. However, it is uncertain whether routine use of IVUS, thrombus aspiration and glycoprotein IIB-IIIA inhibitor is beneficial for improving clinical outcome in patients with ST-segment elevation myocardial infarction (STEMI).
Purpose
The aim of this study was to investigate optimal procedural strategy to improve clinical outcome.
Methods
A total of 6,046 patients who underwent primary percutaneous coronary intervention (PCI) for STEMI were analyzed from the Korean Acute Myocardial Infarction Registry (KAMIR) – National Institute of Health (NIH) database. MACCEs were defined as a composition of all cause death, non-fatal MI, repeat revascularizations including repeated percutaneous coronary intervention and coronary bypass grafting, cerebrovascular accident and rehospitalizations. This research was supported by a fund by Research of Korea Centers for Disease Control and Prevention.
Results
During the primary PCI, potent antiplatelet agents such as prasugrel and ticagrelor were used in 2342 (38.4%). PCI was performed through transradial approach in 1490 (25.2%). Thrombus aspiration and intravascular ultrasound (IVUS) examination was done in 2204 (36.1%) and 1079 (18.1%), respectively. Glycoprotein IIB-IIIA inhibitor was administered in 1295 (21.7%). Among them, potent antiplatelet agents, transradial intervention, IVUS, and thrombus aspiration significantly reduced MACCEs at 1 year. Glycoprotein IIB-IIIA inhibitor was not effective to improved clinical outcome. In Cox-proportional hazards model, potent antiplatelet agents (hazard ratio 0.82, 95% confidence interval 0.67–0.99; p=0.045) and transradial intervention (hazard ratio 0.61, 95% confidence interval 0.47–0.78; p<0.001) was an independent predictor of MACCEs after adjusting for confounding variables. Combined use of potent antiplatelet agents and transradial intervention (hazard ratio 0.54; 95% confidence interval 0.37–0.80; p=0.002) substantially reduced MACCEs at 1 year.
Conclusion
Among evidence based procedures during the primary PCI, combined use of potent antiplatelet agents and transradial intervention was optimal procedural strategy to improve clinical outcome.
Collapse
Affiliation(s)
- Y J Park
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| | - J H Lee
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| | - B E Park
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| | - H N Kim
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| | - S Y Jang
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| | - M H Bae
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| | - D H Yang
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| | - H S Park
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| | - Y Cho
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| | - S C Chae
- Kyungpook National University Hospital, Daegu, Korea (Republic of)
| |
Collapse
|
16
|
Liu HC, Gang EJ, Kim HN, Lim HG, Jung H, Chen R, Abdel-Azim H, Shung KK, Kim YM. Characterizing Deformability of Drug Resistant Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells Using Acoustic Tweezers. Sci Rep 2018; 8:15708. [PMID: 30356155 PMCID: PMC6200731 DOI: 10.1038/s41598-018-34024-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Accepted: 10/05/2018] [Indexed: 12/31/2022] Open
Abstract
The role of cell mechanics in cancer cells is a novel research area that has resulted in the identification of new mechanisms of therapy resistance. Single beam acoustic (SBA) tweezers are a promising technology for the quantification of the mechanical phenotype of cells. Our previous study showed that SBA tweezers can be used to quantify the deformability of adherent breast cancer cell lines. The physical properties of patient-derived (primary) pre-B acute lymphoblastic leukemia (ALL) cells involved in chemotherapeutic resistance have not been widely investigated. Here, we demonstrate the feasibility of analyzing primary pre-B ALL cells from four cases using SBA tweezers. ALL cells showed increased deformability with increasing acoustic pressure of the SBA tweezers. Moreover, ALL cells that are resistant to chemotherapeutic drugs were more deformable than were untreated ALL cells. We demonstrated that SBA tweezers can quantify the deformability of nonadherent leukemia cells and discriminate this mechanical phenotype in chemotherapy-resistant leukemia cells in a contact- and label-free manner.
Collapse
Affiliation(s)
- Hsiao-Chuan Liu
- Department of Biomedical Engineering and NIH Ultrasonic Transducer Resource Center, University of Southern California, 1042 Downey Way, Los Angeles, CA, 90089, USA.,Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California, 4650 Sunset Blvd, Los Angeles, CA, 90027, USA
| | - Eun Ji Gang
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California, 4650 Sunset Blvd, Los Angeles, CA, 90027, USA
| | - Hye Na Kim
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California, 4650 Sunset Blvd, Los Angeles, CA, 90027, USA
| | - Hae Gyun Lim
- Department of Creative IT Engineering and Future IT Innovation Laboratory, Pohang University of Science and Technology, 77 Cheongam-ro, Nam-gu, Pohang, Gyeongbuk, 37673, Republic of Korea
| | - Hayong Jung
- Department of Biomedical Engineering and NIH Ultrasonic Transducer Resource Center, University of Southern California, 1042 Downey Way, Los Angeles, CA, 90089, USA
| | - Ruimin Chen
- Department of Biomedical Engineering and NIH Ultrasonic Transducer Resource Center, University of Southern California, 1042 Downey Way, Los Angeles, CA, 90089, USA
| | - Hisham Abdel-Azim
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California, 4650 Sunset Blvd, Los Angeles, CA, 90027, USA
| | - K Kirk Shung
- Department of Biomedical Engineering and NIH Ultrasonic Transducer Resource Center, University of Southern California, 1042 Downey Way, Los Angeles, CA, 90089, USA.
| | - Yong-Mi Kim
- Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California, 4650 Sunset Blvd, Los Angeles, CA, 90027, USA.
| |
Collapse
|
17
|
Fousek K, Watanabe J, An X, George A, Samaha H, Navai S, Byrd TT, Kirzner J, Kim HN, Jang A, Joseph S, Baker M, Hegde M, Varadarajan N, Heisterkamp N, Abdel-Azim H, Ahmed N. Abstract A50: Trivalent CAR T cells mitigate CD19-negative relapse and improve tumor control in primary pre-B cell acute lymphoblastic leukemia (B-ALL). Cancer Immunol Res 2018. [DOI: 10.1158/2326-6074.tumimm17-a50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
B-acute lymphoblastic leukemia (B-ALL) is the most common malignancy in children, and limited treatment options exist for patients with relapsed or refractory disease. Cellular immunotherapy, specifically chimeric antigen receptor (CAR) T cells targeting CD19 have demonstrated remarkable efficacy in treating B-ALL. However, recent reports show that up to 40% of patients who relapse after CD19 CAR T cell therapy have CD19-negative disease, justifying a need to expand CAR T cell therapy for B-ALL to include additional tumor-associated antigens (TAAs).
Here, we hypothesize that targeting three distinct leukemia antigens CD19, CD20, and CD22 will improve B-ALL therapy outcomes and control disease progression during CD19-negative relapse.
We designed two trivalent CAR T cell products with exodomains derived from single chain variable fragments (ScFv) targeting CD19 (FMC63 ScFv), CD20 (Rituximab ScFv), and CD22 (m971 ScFv) fused to the intracellular signaling domains of the co-stimulatory molecule 4-1BB and the T-cell receptor zeta chain (2nd generation). Using viral 2A intervening sequences for near equal expression, the first T cell product expresses the three CARs individually on the surface of a single T cell (TriCAR). The second T cell product expresses a traditional single CAR targeting CD19 and a second bi-specific CAR targeting CD20 and CD22 through a tandem arrangement (SideCAR). Donor T cells were successfully engineered to express the CARs using a retroviral system and the surface expression of these CAR molecules was confirmed by flow cytometry. Using a target expression validated panel of patient derived B-ALL cells (US7 CD19/CD20/CD22 +++/++/++, LAX-56 +++/+/+, TXL-2 +++/++/+++), we observed that TriCAR and SideCAR T cells killed ALL cells more robustly than CD19 CAR T cells at low effector to target ratios (E:T) in a 51Cr release cytotoxicity assay. TriCAR and SideCAR T cells secreted similar levels of IFN-gamma; when compared to CD19 CAR T cells demonstrating a safety profile very similar to the CD19 CAR T cells, but with enhanced killing. Further, we tested the efficacy of TriCAR and SideCAR T cells against primary CD19-negative relapsed bone marrow samples and CRISPR CD19 knockouts of the three primary ALL samples. Using these models of CD19 escape we demonstrated that trivalent CAR T cells effectively mitigated CD19 negative relapse, producing IFN-gamma; and killing CD19-negative primary ALL, while CD19 CAR T cells remained ineffective. In conclusion, trivalent CAR T cells are effective at targeting primary ALL cells of varying antigen profiles and mitigating CD19 negative relapse. This strategy has potential for use as a front-line therapy for primary ALL as well as a salvage therapy for patients with CD19-negative disease relapse.
Citation Format: Kristen Fousek, Junji Watanabe, Xingyue An, Ann George, Heba Samaha, Shoba Navai, Tiara T. Byrd, Jonathan Kirzner, Hye Na Kim, Albert Jang, Sujith Joseph, Matthew Baker, Meenakshi Hegde, Navin Varadarajan, Nora Heisterkamp, Hisham Abdel-Azim, Nabil Ahmed. Trivalent CAR T cells mitigate CD19-negative relapse and improve tumor control in primary pre-B cell acute lymphoblastic leukemia (B-ALL) [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2017 Oct 1-4; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2018;6(9 Suppl):Abstract nr A50.
Collapse
Affiliation(s)
| | | | | | - Ann George
- 2Children’s Hospital Los Angeles, Los Angeles, CA,
| | | | | | | | | | - Hye Na Kim
- 2Children’s Hospital Los Angeles, Los Angeles, CA,
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Lee JH, Park BE, Park YJ, Kim HN, Kim NK, Song JH, Jang SY, Bae MH, Yang DH, Park HS, Cho Y, Chae SC, Jeong MH. P5533Impact of thrombus aspiration and Glycoprotein IIb/IIIa inhibitor between new antiplatelet agents and clopidogrel in patients undergoing primary percutaneous coronary intervention. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- J H Lee
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - B E Park
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - Y J Park
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - H N Kim
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - N K Kim
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - J H Song
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - S Y Jang
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - M H Bae
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - D H Yang
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - H S Park
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - Y Cho
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - S C Chae
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - M H Jeong
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | | |
Collapse
|
19
|
Lee JH, Pakr BE, Park YJ, Kim HN, Song JH, Kim NK, Jang SY, Bae MH, Yang DH, Park HS, Cho Y, Chae SC, Jeong MH. P5575Practice-level variation in use of optimal medical treatment during hospitalization: a multi-level methodological approach. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- J H Lee
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - B E Pakr
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - Y J Park
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - H N Kim
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - J H Song
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - N K Kim
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - S Y Jang
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - M H Bae
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - D H Yang
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - H S Park
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - Y Cho
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - S C Chae
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - M H Jeong
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | | |
Collapse
|
20
|
Lee JH, Yoon JY, Park BE, Park YJ, Kim HN, Kim NK, Jang SY, Bae MH, Yang DH, Park HS, Cho Y, Chae SC. P3576Impact of intravascular ultrasound and final kissing balloon dilatation on 10-year clinical outcome in percutaneous revascularization with 1-stent strategy for left main coronary artery stenosis. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- J H Lee
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - J Y Yoon
- Gumi Cha Hospital, Internal Medicine, Gumi, Korea Republic of
| | - B E Park
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - Y J Park
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - H N Kim
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - N K Kim
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - S Y Jang
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - M H Bae
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - D H Yang
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - H S Park
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - Y Cho
- Kyungpook National University Hospital, Daegu, Korea Republic of
| | - S C Chae
- Kyungpook National University Hospital, Daegu, Korea Republic of
| |
Collapse
|
21
|
Fousek K, Watanabe J, George A, An X, Samaha HS, Navai SA, Byrd TT, Jang A, Kim HN, Joseph S, Baker M, Varadarajan N, Hegde MG, Kim YM, Heisterkamp N, Abdel-Azim HM, Ahmed NM. Targeting CD19-negative relapsed B-acute lymphoblastic leukemia using trivalent CAR T cells. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.5_suppl.121] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
121 Background: Chimeric antigen receptor (CAR) T cells targeting CD19 have shown remarkable efficacy in treating relapsed B cell acute lymphoblastic leukemia (B-ALL). However, recent reports show that up to 40% of patients who relapse after CD19 CAR T cell therapy have CD19-negative disease, justifying a need to expand CAR T cell therapy for B-ALL to include additional tumor-associated antigens. We hypothesize that targeting CD19, CD20, and CD22 will improve B-ALL therapy outcomes and control disease progression during CD19-negative relapse. Methods: We designed two trivalent CAR T cell products with exodomains derived from single chain variable fragments (ScFv) targeting CD19, CD20, and CD22. Each CAR contains the 4-1BB and T-cell receptor zeta chains. Donor T cells were engineered to express the CARs using a retroviral system. We used primary CD19-negative relapsed bone marrow samples and CRISPR CD19 knockouts of primary ALL to model CD19 escape and standard cytotoxicity and immune assays to evaluate anti-tumor efficacy. Results: Due to the use of viral 2A sequences we detected near equal expression of each CAR by flow cytometry. The first T cell product expresses three CARs individually (TriCAR), and the second expresses a single CAR targeting CD19 and a second bi-specific CAR targeting CD20 and CD22 via a tandem arrangement (SideCAR). Using primary B-ALL cells, we observed that TriCAR and SideCAR T cells killed ALL cells more robustly than CD19 CAR T cells at low E:T ratios. Further, in ImageStream analysis of single cell interactions between CAR T cells and primary B-ALL cells, TriCAR T cells exhibited increased actin polymerization compared to CD19 CAR T cells, suggesting remodeling and increased cell activation. Finally, in multiple models of CD19 escape in primary ALL, we showed that trivalent CAR T cells mitigated CD19 negative relapse, producing IFN-γ/TNF-α and killing CD19-negative primary ALL, while CD19 CAR T cells remained ineffective. Conclusions: Trivalent CAR T cells effectively target primary ALL cells with varying antigen profiles and mitigate CD19-negative relapse. This strategy has the potential for use as an initial CAR therapy in relapsed ALL or a salvage therapy for patients with CD19-negative disease.
Collapse
Affiliation(s)
| | | | - Ann George
- Children's Hospital Los Angeles, Los Angeles, CA
| | | | | | | | | | | | - Hye Na Kim
- Children's Hospital Los Angeles, Los Angeles, CA
| | | | | | | | | | - Yong-Mi Kim
- Children's Hospital Los Angeles, Los Angeles, CA
| | | | | | | |
Collapse
|
22
|
Duchartre Y, Bachl S, Kim HN, Gang EJ, Lee S, Liu HC, Shung K, Xu R, Kruse A, Tachas G, Bonig H, Kim YM. Effects of CD49d-targeted antisense-oligonucleotide on α4 integrin expression and function of acute lymphoblastic leukemia cells: Results of in vitro and in vivo studies. PLoS One 2017; 12:e0187684. [PMID: 29117236 PMCID: PMC5678723 DOI: 10.1371/journal.pone.0187684] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2017] [Accepted: 10/24/2017] [Indexed: 11/23/2022] Open
Abstract
We recently demonstrated the effectiveness of blocking CD49d with anti-functional antibodies or small molecule inhibitors as a rational targeted approach to the treatment of acute leukemia in combination with chemotherapy. Antisense oligonucleotide promises to be no less specific than antibodies and inhibitors, but more interesting for pharmacokinetics and pharmacodynamics. We addressed this using the published CD49d antisense drug ATL1102. In vitro, we incubated/nucleofected the ALL cell line Kasumi-2 with ATL1102. In vivo, immunodeficient hosts were engrafted with primary ALL cells and treated with ATL1102. Changes in expression of CD49d mRNA and CD49d protein, and of cooperating gene products, including ß1 integrin and CXCR4, as well as survival in the mouse experiments were quantified. We observed dose-dependent down-regulation of CD49d mRNA and protein levels and its partner integrin ß1 cell surface protein level and, up-regulation of CXCR4 surface expression. The suppression was more pronounced after nucleofection than after incubation, where down-regulation was significant only at the higher doses. In vivo effects of ATL1102 were not sufficient to translate into “clinical” benefit in the leukemia model. In summary, antisense oligonucleotides are successful tools for specifically modulating gene expression but sufficient delivery to down-regulate CD49d in vivo may be difficult to achieve.
Collapse
Affiliation(s)
- Yann Duchartre
- Department of Pediatrics, Division of Hematology and Oncology, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, United States of America
| | - Stefanie Bachl
- Department of Pediatrics, Division of Hematology and Oncology, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, United States of America
- Institute for Transfusion Medicine and Immunohematology, Goethe University, and German Red Cross Blood Service Baden-Württemberg-Hessen, Frankfurt, Germany
| | - Hye Na Kim
- Department of Pediatrics, Division of Hematology and Oncology, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, United States of America
| | - Eun Ji Gang
- Department of Pediatrics, Division of Hematology and Oncology, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, United States of America
| | - Solah Lee
- Department of Pediatrics, Division of Hematology and Oncology, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, United States of America
| | - Hsiao-chuan Liu
- Department of Biomedical Engineering, University of Southern California, Los Angeles, United States of America
| | - Kirk Shung
- Department of Biomedical Engineering, University of Southern California, Los Angeles, United States of America
| | - Ruth Xu
- Department of Pediatrics, Division of Hematology and Oncology, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, United States of America
| | - Aaron Kruse
- Department of Pediatrics, Division of Hematology and Oncology, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, United States of America
- Department of Pathology, University of Southern California, Los Angeles, United States of America
| | - George Tachas
- Antisense Therapeutics Limited, Toorak, Victoria, Australia
| | - Halvard Bonig
- Institute for Transfusion Medicine and Immunohematology, Goethe University, and German Red Cross Blood Service Baden-Württemberg-Hessen, Frankfurt, Germany
- Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, United States of America
| | - Yong-Mi Kim
- Department of Pediatrics, Division of Hematology and Oncology, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, United States of America
- * E-mail:
| |
Collapse
|
23
|
Adam E, Kim HN, Gang EJ, Schnair C, Lee S, Lee S, Khazal S, Kosoyan O, Konopleva M, Parekh C, Bhojwani D, Wayne AS, Abdel-Azim H, Heisterkamp N, Kim YM. The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL. Cancers (Basel) 2017; 9:cancers9090121. [PMID: 28891959 PMCID: PMC5615336 DOI: 10.3390/cancers9090121] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Revised: 09/06/2017] [Accepted: 09/06/2017] [Indexed: 11/16/2022] Open
Abstract
The quest continues for targeted therapies to reduce the morbidity of chemotherapy and to improve the response of resistant leukemia. Adhesion of acute lymphoblastic leukemia (ALL) cells to bone marrow stromal cells triggers intracellular signals that promote cell-adhesion-mediated drug resistance (CAM-DR). Idelalisib, an U.S. Food and Drug Administration (FDA)-approved PI3Kδ-specific inhibitor has been shown to be effective in CLL in down-regulating p-Akt and prolonging survival in combination with Rituximab; herein we explore the possibility of its use in B ALL and probe the mechanism of action. Primary B ALL in contact with OP9 stromal cells showed increased p-Aktser473. Idelalisib decreased p-Akt in patient samples of ALL with diverse genetic lesions. Addition of idelalisib to vincristine inhibited proliferation when compared to vincristine monotherapy in a subset of samples tested. Idelalisib inhibited ALL migration to SDF-1α in vitro and blocked homing of ALL cells to the bone marrow in vivo. This report tests PI3Kδ inhibitors in a more diverse group of ALL than has been previously reported and is the first published report of idelalisib inhibiting homing of ALL cells to bone marrow. Our data support further pre-clinical evaluation of idelalisib for the therapy of B ALL.
Collapse
Affiliation(s)
- Etai Adam
- Department of Pediatrics, Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
| | - Hye Na Kim
- Department of Pediatrics, Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
| | - Eun Ji Gang
- Department of Pediatrics, Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
| | - Caitlin Schnair
- Department of Pediatrics, Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
| | - Solomon Lee
- Department of Pediatrics, Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
| | - Solah Lee
- Department of Pediatrics, Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
| | - Sajad Khazal
- Department of Pediatrics, Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
- Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
| | - Osanna Kosoyan
- Department of Pediatrics, Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
| | - Marina Konopleva
- Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
| | - Chintan Parekh
- Department of Pediatrics, Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
| | - Deepa Bhojwani
- Department of Pediatrics, Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
| | - Alan S Wayne
- Department of Pediatrics, Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
| | - Hisham Abdel-Azim
- Department of Pediatrics, Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
| | - Nora Heisterkamp
- Department of Pediatrics, Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
| | - Yong-Mi Kim
- Department of Pediatrics, Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
| |
Collapse
|
24
|
Narayanan R, Kim HN, Narayanan NK, Nargi D, Narayanan B. [Retracted] Epidermal growth factor-stimulated human cervical cancer cell growth is associated with EGFR and cyclin D1 activation, independent of COX-2 expression levels. Int J Oncol 2016; 50:337. [PMID: 27779652 PMCID: PMC5182009 DOI: 10.3892/ijo.2016.3737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2010] [Accepted: 04/12/2010] [Indexed: 11/18/2022] Open
Affiliation(s)
- Rajkishen Narayanan
- New York University School of Medicine, Department of Environmental Medicine, Tuxedo, NY, USA
| | - Hye Na Kim
- New York University School of Medicine, Department of Environmental Medicine, Tuxedo, NY, USA
| | - Narayanan K Narayanan
- New York University School of Medicine, Department of Environmental Medicine, Tuxedo, NY, USA
| | - Dominick Nargi
- New York University School of Medicine, Department of Environmental Medicine, Tuxedo, NY, USA
| | - Bhagavathi Narayanan
- New York University School of Medicine, Department of Environmental Medicine, Tuxedo, NY, USA
| |
Collapse
|
25
|
|
26
|
Ji M, Hur M, Kim HN, Moon HW, Yun YM, Kim SY. Abrupt thrombocytopenia with sustained trilineage engraftment in a stem cell transplant recipient. Int J Lab Hematol 2015; 37:e106-8. [PMID: 25754932 DOI: 10.1111/ijlh.12338] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- M Ji
- Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea
| | - M Hur
- Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea.
| | - H N Kim
- Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea
| | - H-W Moon
- Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea
| | - Y-M Yun
- Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea
| | - S-Y Kim
- Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea
| |
Collapse
|
27
|
Hsieh YT, Gang EJ, Shishido SN, Kim HN, Pham J, Khazal S, Osborne A, Esguerra ZA, Kwok E, Jang J, Bonig H, Biediger RJ, Vanderslice P, Kim YM. Effects of the small-molecule inhibitor of integrin α4, TBC3486, on pre-B-ALL cells. Leukemia 2014; 28:2101-4. [PMID: 24903479 PMCID: PMC4190402 DOI: 10.1038/leu.2014.182] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2014] [Indexed: 11/09/2022]
Affiliation(s)
- Y T Hsieh
- Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
| | - E J Gang
- Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
| | - S N Shishido
- Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
| | - H N Kim
- Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
| | - J Pham
- Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
| | - S Khazal
- Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
| | - A Osborne
- Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
| | - Z A Esguerra
- Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
| | - E Kwok
- Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
| | - J Jang
- Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
| | - H Bonig
- Institute for Transfusion Medicine and Immunohematology, Johann-Wolfgang-Goethe University, Frankfurt, Germany
| | - R J Biediger
- Wafic Said Molecular Cardiology Research Laboratory, Texas Heart Institute, Houston, TX, USA
| | - P Vanderslice
- Wafic Said Molecular Cardiology Research Laboratory, Texas Heart Institute, Houston, TX, USA
| | - Y M Kim
- Division of Hematology and Oncology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
| |
Collapse
|
28
|
Piao JM, Shin MH, Kim HN, Song HR, Kweon SS, Choi JS, Shim HJ, Hwang JE, Bae WK, Kim SH, Choi YD, Cui LH. Replication of results of genome-wide association studies on esophageal squamous cell carcinoma susceptibility loci in a Korean population. Dis Esophagus 2013; 27:798-801. [PMID: 24152165 DOI: 10.1111/dote.12155] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Two recent genome-wide association studies have identified that the rs2274223 single-nucleotide polymorphism inphospholipase C epsilon 1 and the single-nucleotide polymorphism rs13042395 in C20orf54 are involved in esophageal squamous cell carcinoma (ESCC) in Chinese populations. We hypothesized that genetic polymorphisms of phospholipase C epsilon 1 and C20orf54 are also associated with ESCC in a Korean population. The rs2274223 and rs13042395 genotyping was performed using high-resolution melting analysis. The rs2274223 GG genotype was significantly associated with an increased risk of ESCC (odds ratio [OR]=1.86, 95% confidence interval [CI]=1.08-3.25) compared with the rs2274223 AA genotype. The rs13042395 G allele showed a significantly decreased risk of ESCC in the younger age group (OR=0.71, 95% CI=0.52-0.97) and no significant association in the older group (OR=1.19, 95% CI=0.87-1.62). We observed that the rs2274223 polymorphism was associated with an increased risk of ESCC in this Korean case-control study and that age may modify the association between the rs13042395 polymorphism and the risk of ESCC.
Collapse
Affiliation(s)
- J-M Piao
- Department of Public Health, Qingdao University Medical College, Qingdao, China
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Kim HN, Kim DE, Hwang JE, Bae WK, Cho SH, Joo YE, Choi KH, Chung IJ, Shim HJ. Paradoxical cerebral embolism during endoscopic esophageal stenting in a patient with esophageal cancer. Endoscopy 2013; 44 Suppl 2 UCTN:E406-7. [PMID: 23169038 DOI: 10.1055/s-0032-1310143] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Affiliation(s)
- H N Kim
- Division of Hematology-Oncology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea
| | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Khang G, Lee SK, Kim HN, Silva-Correia J, Gomes ME, Viegas CAA, Dias IR, Oliveira JM, Reis RL. Biological evaluation of intervertebral disc cells in different formulations of gellan gum-based hydrogels. J Tissue Eng Regen Med 2012; 9:265-75. [PMID: 23225767 DOI: 10.1002/term.1625] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2012] [Accepted: 08/28/2012] [Indexed: 11/07/2022]
Abstract
Gellan gum (GG)-based hydrogels are advantageous in tissue engineering not only due to their ability to retain large quantities of water and provide a similar environment to that of natural extracellular matrix (ECM), but also because they can gelify in situ in seconds. Their mechanical properties can be fine-tuned to mimic natural tissues such as the nucleus pulposus (NP). This study produced different formulations of GG hydrogels by mixing varying amounts of methacrylated (GG-MA) and high-acyl gellan gums (HA-GG) for applications as acellular and cellular NP substitutes. The hydrogels were physicochemically characterized by dynamic mechanical analysis. Degradation and swelling abilities were assessed by soaking in a phosphate buffered saline solution for up to 170 h. Results showed that as HA-GG content increased, the modulus of the hydrogels decreased. Moreover, increases in HA-GG content induced greater weight loss in the GG-MA/HA-GG formulation compared to GG-MA hydrogel. Potential cytotoxicity of the hydrogel was assessed by culturing rabbit NP cells up to 7 days. An MTS assay was performed by seeding rabbit NP cells onto the surface of 3D hydrogel disc formulations. Viability of rabbit NP cells encapsulated within the different hydrogel formulations was also evaluated by Calcein-AM and ATP assays. Results showed that tunable GG-MA/HA-GG hydrogels were non-cytotoxic and supported viability of rabbit NP cells.
Collapse
Affiliation(s)
- G Khang
- Chonbuk National University, Department of Polymer-Nano Science and Technology, Jeonju, Korea; Chonbuk National University, Department of BIN Fusion Technology, Jeonju, Korea
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Ji YS, Kim HN, Park HJ, Lee JE, Yeo SY, Yang JS, Park SY, Yoon HS, Cho GS, Franz CMAP, Bomba A, Shin HK, Holzapfel WH. Modulation of the murine microbiome with a concomitant anti-obesity effect by Lactobacillus rhamnosus GG and Lactobacillus sakei NR28. Benef Microbes 2012; 3:13-22. [PMID: 22348905 DOI: 10.3920/bm2011.0046] [Citation(s) in RCA: 86] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
The microbiota of the gastrointestinal tract (GIT) constitutes the major part of the total human microbiome and is considered to be an important regulator of human health and host metabolism. Numerous investigations in recent years have focused on the connection between the human microbiota and metabolic diseases such as obesity, type II diabetes and atherosclerosis. Yet, little is known about the impact of probiotic consumption on the GIT microbial population and the potential effect on chronic diseases. In this study, the modulation of the microbial community in the murine small intestine resulting from probiotic feeding was investigated and was found to be associated with an anti-obesity effect. Changes in the microbiota of the mouse faeces and small intestine were monitored using quantitative real-time PCR and by following the mRNA expression levels of various obesity-related biomarkers following probiotic feeding in a mouse model. Lactobacillus rhamnosus GG and Lactobacillus sakei NR28 (a putative probiotic strain isolated from kimchi) were administered at a daily level of approximately 1×10(8) viable bacteria per mouse (C57BL/6J mice) for up to three weeks. Feeding these strains resulted in a significant reduction of epididymal fat mass, as well as obesity-related biomarkers like acetyl-CoA carboxylase, fatty acid synthase, and stearoyl-CoA desaturase-1 in the liver. The total number and ratio of the microbial groups, i.e. Firmicutes, Bacteroidetes, Clostridium cluster I and XIVab, and Lactobacillus spp. were modulated in the small intestine, and the Firmicutes:Bacteroidetes ratio was decreased. In contrast, no noticeable effect of probiotic feeding could be detected on the faecal microbiota, neither quantitatively, nor with regard to the bacterial groups (Firmicutes, Bacteroidetes, Clostridium cluster I and XIVab, and Lactobacillus spp.) studied.
Collapse
Affiliation(s)
- Y S Ji
- School of Life Science, Handong Global University, Pohang, Gyungbuk, Republic of Korea
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Kim HN, Narayanan NK, Lasano S, Narayanan B. Modulation of PGE2-induced EP4 expression on snail signaling and the impact on epithelial-mesenchymal transition: significance of EP4 antagonism. Anticancer Res 2011; 31:4347-4357. [PMID: 22199300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
BACKGROUND Although significant accumulation of prostaglandin E(2) (PGE(2)) in the human prostate cancer tissues has been reported, there is lack of substantial evidence regarding the key role of PGE(2)-induced E-prostanoid-4 receptor (EP4) on Snail, a master regulator of epithelial mesenchymal transition (EMT). In this study, we investigated a novel connection between PGE(2)-induced EP4 and Snail (encodes DNA binding zinc finger protein that acts as transcriptional repressor) signaling in prostate cancer. MATERIALS AND METHODS To investigate the key role of serum PGE(2), EP4, p-Akt and Snail in prostate cancer progression, we used prostate-specific phosphatase and tensin homolog (PTEN)-knockout (PTEN-KO) mice of different age groups from 4 to 28 weeks. To determine the EP4-specific interaction with Snail in prostate cancer, we used cell-based assays, including siRNA knockdown, and treatment with EP4 antagonist. RESULTS An interaction between EP4 with Snail was evident in prostate-specific PTEN-KO mice that showed an elevated level of PGE(2) in the serum and of EP4, p-Akt and Snail in the tissues. Prostate cancer cells transfected with EP4-siRNA and treatments with EP4 antagonist suggest a link between EP4, and Snail activation, potentially via p-Akt. Cells treated with EP4 antagonist exhibited a significant decrease in Snail, mesenchymal markers and cell migration, and cell cycle arrest with a gain in E-cadherin levels. CONCLUSION Our findings provide key evidence that support there being a role of PGE(2)/EP4/p-Akt in Snail signaling and conferring cell survival advantage. Cancer progression via EMT can be reversed by an EP4 antagonist in this model of prostate cancer.
Collapse
Affiliation(s)
- Hye Na Kim
- New York University School of Medicine, Department of Environmental Medicine, Tuxedo, NY, USA
| | | | | | | |
Collapse
|
33
|
Piao JM, Kim HN, Song HR, Kweon SS, Choi JS, Yoon JY, Chung IJ, Kim SH, Shin MH. p53 codon 72 polymorphism and the risk of esophageal cancer: a Korean case-control study. Dis Esophagus 2011; 24:596-600. [PMID: 21595775 DOI: 10.1111/j.1442-2050.2011.01203.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The aim of this study was to assess whether p53 codon 72 polymorphism is associated with an increased risk of esophageal cancer (EC) in South Korea. We conducted a case-control study including 340 patients with EC, and 1700 controls. P53 codon 72 polymorphism was determined by real-time polymerase chain reaction. The frequencies of p53 codon 72 polymorphisms (Arg/Arg, Arg/Pro, and Pro/Pro) in EC were 39.4%, 45.6%, and 15.0%, respectively; frequencies in the controls were 43.2%, 45.6%, and 11.2%, respectively. Compared with the Arg/Arg genotype, the OR of the Arg/Pro genotype was 1.09 (95% CI = 0.85-1.41) and that of the Pro/Pro genotype was 1.47 (95% CI = 1.02-2.11) for EC overall. When adjusted by age, gender, and smoking status, the OR of the Arg/Pro genotype was 1.24 (95% CI = 0.92-1.67) and that of the Pro/Pro genotype was 1.77 (95% CI = 1.15-2.74) for EC overall. In never-smokers and ever-smokers, the OR of the Arg/Pro genotype was 0.59 (95% CI = 0.37-0.95) and 1.39 (95% CI = 1.00-1.91), respectively, and there was a significant difference in the homogeneity test (P= 0.011). We observed that the p53 codon 72 polymorphism was associated with an increased risk of EC in this Korean case-control study, and smoking status modified the association between the p53 codon 72 polymorphism and the risk of EC.
Collapse
Affiliation(s)
- J-M Piao
- Department of Preventive Medicine,Yanbian University College of Medicine, Yanji, Jilin Province, China
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Kim KM, Brown JK, Kim KJ, Choi HS, Kim HN, Rhee Y, Lim SK. Differences in femoral neck geometry associated with age and ethnicity. Osteoporos Int 2011; 22:2165-74. [PMID: 20976592 DOI: 10.1007/s00198-010-1459-z] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/06/2010] [Accepted: 08/31/2010] [Indexed: 11/27/2022]
Abstract
SUMMARY We studied femoral geometry in relation to age and ethnicity in a cross-sectional study. Age-associated cortical thinning showed the most pronounced effect, and Koreans studied here had thicker cortices and lower buckling ratios than those reported for other races. Cortical thickness may thus be a major determinant of hip fracture risk. INTRODUCTION The rate of hip fracture varies by age and ethnicity. The geometric properties of the femur influence femoral strength and fragility, but differences in femoral geometry according to age and ethnicity are poorly understood. To explain the high prevalence of hip fractures in the elderly and the relatively low hip fracture rate in Asian populations, we studied age-related changes and ethnic differences in femoral geometry. METHODS We recruited 214 peri- or postmenopausal women aged 46 to 85 years (mean age, 60.6 years). Their proximal femoral bone mineral densities (BMD) were measured by quantitative computed tomography and further analyzed geometric properties. RESULTS We observed large declines in trabecular volumetric bone mineral density associated with aging (33.03% less than the reference value in the oldest group, respectively). Cortical thickness decreased remarkably with age as well, and only 53.94% of the baseline value remained in the oldest group. As a result, the cortical buckling ratio increased geometrically and reached 239.14% of the reference value in the oldest group. In comparisons with other ethnic groups, Korean subjects had thicker cortices than their American, European, and African counterparts. CONCLUSIONS In this cross-sectional study, cortical thickness showed a pronounced age-associated decrease, and the cortical buckling ratio showed a strong age-associated increase. This may in part explain the higher rates of hip fractures in the elderly. When compared with other races, Asians had thicker cortical bone and lower buckling ratios, which may partially explain the lower prevalence of hip fractures in Asians.
Collapse
Affiliation(s)
- K M Kim
- Division of Endocrinology, Department of Internal Medicine, and Institute of Endocrine Research, Yonsei University College of Medicine, 250 Seongsan-ro, Seodaemun-gu, Seoul, 120-752, South Korea
| | | | | | | | | | | | | |
Collapse
|
35
|
Aamodt K, Abrahantes Quintana A, Adamová D, Adare AM, Aggarwal MM, Aglieri Rinella G, Agocs AG, Aguilar Salazar S, Ahammed Z, Ahmad N, Ahmad Masoodi A, Ahn SU, Akindinov A, Aleksandrov D, Alessandro B, Alfaro Molina R, Alici A, Alkin A, Almaráz Aviña E, Alt T, Altini V, Altinpinar S, Altsybeev I, Andrei C, Andronic A, Anguelov V, Anson C, Antičić T, Antinori F, Antonioli P, Aphecetche L, Appelshäuser H, Arbor N, Arcelli S, Arend A, Armesto N, Arnaldi R, Aronsson T, Arsene IC, Asryan A, Augustinus A, Averbeck R, Awes TC, Aystö J, Azmi MD, Bach M, Badalà A, Baek YW, Bagnasco S, Bailhache R, Bala R, Baldini Ferroli R, Baldisseri A, Baldit A, Bán J, Barbera R, Barile F, Barnaföldi GG, Barnby LS, Barret V, Bartke J, Basile M, Bastid N, Bathen B, Batigne G, Batyunya B, Baumann C, Bearden IG, Beck H, Belikov I, Bellini F, Bellwied R, Belmont-Moreno E, Beole S, Berceanu I, Bercuci A, Berdermann E, Berdnikov Y, Betev L, Bhasin A, Bhati AK, Bianchi L, Bianchi N, Bianchin C, Bielčík J, Bielčíková J, Bilandzic A, Biolcati E, Blanc A, Blanco F, Blanco F, Blau D, Blume C, Boccioli M, Bock N, Bogdanov A, Bøggild H, Bogolyubsky M, Boldizsár L, Bombara M, Bombonati C, Book J, Borel H, Bortolin C, Bose S, Bossú F, Botje M, Böttger S, Boyer B, Braun-Munzinger P, Bravina L, Bregant M, Breitner T, Broz M, Brun R, Bruna E, Bruno GE, Budnikov D, Buesching H, Busch O, Buthelezi Z, Caffarri D, Cai X, Caines H, Calvo Villar E, Camerini P, Canoa Roman V, Cara Romeo G, Carena F, Carena W, Carminati F, Casanova Díaz A, Caselle M, Castillo Castellanos J, Catanescu V, Cavicchioli C, Cerello P, Chang B, Chapeland S, Charvet JL, Chattopadhyay S, Chattopadhyay S, Cherney M, Cheshkov C, Cheynis B, Chiavassa E, Chibante Barroso V, Chinellato DD, Chochula P, Chojnacki M, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Cicalo C, Cifarelli L, Cindolo F, Cleymans J, Coccetti F, Coffin JP, Coli S, Conesa Balbastre G, Conesa Del Valle Z, Constantin P, Contin G, Contreras JG, Cormier TM, Corrales Morales Y, Cortés Maldonado I, Cortese P, Cosentino MR, Costa F, Cotallo ME, Crescio E, Crochet P, Cuautle E, Cunqueiro L, Erasmo GD, Dainese A, Dalsgaard HH, Danu A, Das D, Das I, Dash A, Dash S, De S, De Azevedo Moregula A, de Barros GOV, De Caro A, de Cataldo G, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Pasquale S, De Remigis R, de Rooij R, Delagrange H, Delgado Mercado Y, Dellacasa G, Deloff A, Demanov V, Dénes E, Deppman A, Di Bari D, Di Giglio C, Di Liberto S, Di Mauro A, Di Nezza P, Dietel T, Divià R, Djuvsland Ø, Dobrin A, Dobrowolski T, Domínguez I, Dönigus B, Dordic O, Driga O, Dubey AK, Ducroux L, Dupieux P, Dutta Majumdar AK, Dutta Majumdar MR, Elia D, Emschermann D, Engel H, Erdal HA, Espagnon B, Estienne M, Esumi S, Evans D, Evrard S, Eyyubova G, Fabjan CW, Fabris D, Faivre J, Falchieri D, Fantoni A, Fasel M, Fearick R, Fedunov A, Fehlker D, Fekete V, Felea D, Feofilov G, Fernández Téllez A, Ferretti A, Ferretti R, Figueredo MAS, Filchagin S, Fini R, Finogeev D, Fionda FM, Fiore EM, Floris M, Foertsch S, Foka P, Fokin S, Fragiacomo E, Fragkiadakis M, Frankenfeld U, Fuchs U, Furano F, Furget C, Fusco Girard M, Gaardhøje JJ, Gadrat S, Gagliardi M, Gago A, Gallio M, Ganoti P, Garabatos C, Gemme R, Gerhard J, Germain M, Geuna C, Gheata A, Gheata M, Ghidini B, Ghosh P, Girard MR, Giraudo G, Giubellino P, Gladysz-Dziadus E, Glässel P, Gomez R, González-Trueba LH, González-Zamora P, González Santos H, Gorbunov S, Gotovac S, Grabski V, Grajcarek R, Grelli A, Grigoras A, Grigoras C, Grigoriev V, Grigoryan A, Grigoryan S, Grinyov B, Grion N, Gros P, Grosse-Oetringhaus JF, Grossiord JY, Grosso R, Guber F, Guernane R, Guerra Gutierrez C, Guerzoni B, Gulbrandsen K, Gulkanyan H, Gunji T, Gupta A, Gupta R, Gutbrod H, Haaland Ø, Hadjidakis C, Haiduc M, Hamagaki H, Hamar G, Harris JW, Hartig M, Hasch D, Hasegan D, Hatzifotiadou D, Hayrapetyan A, Heide M, Heinz M, Helstrup H, Herghelegiu A, Hernández C, Herrera Corral G, Herrmann N, Hetland KF, Hicks B, Hille PT, Hippolyte B, Horaguchi T, Hori Y, Hristov P, Hřivnáčová I, Huang M, Huber S, Humanic TJ, Hwang DS, Ichou R, Ilkaev R, Ilkiv I, Inaba M, Incani E, Innocenti GM, Innocenti PG, Ippolitov M, Irfan M, Ivan C, Ivanov A, Ivanov M, Ivanov V, Jachołkowski A, Jacobs PM, Jancurová L, Jangal S, Janik R, Jayarathna SP, Jena S, Jirden L, Jones GT, Jones PG, Jovanović P, Jung H, Jung W, Jusko A, Kalcher S, Kaliňák P, Kalisky M, Kalliokoski T, Kalweit A, Kamermans R, Kanaki K, Kang E, Kang JH, Kaplin V, Karavichev O, Karavicheva T, Karpechev E, Kazantsev A, Kebschull U, Keidel R, Khan MM, Khanzadeev A, Kharlov Y, Kileng B, Kim DJ, Kim DS, Kim DW, Kim HN, Kim JH, Kim JS, Kim M, Kim M, Kim S, Kim SH, Kirsch S, Kisel I, Kiselev S, Kisiel A, Klay JL, Klein J, Klein-Bösing C, Kliemant M, Klovning A, Kluge A, Knichel ML, Koch K, Köhler MK, Kolevatov R, Kolojvari A, Kondratiev V, Kondratyeva N, Konevskih A, Kornaś E, Kottachchi Kankanamge Don C, Kour R, Kowalski M, Kox S, Koyithatta Meethaleveedu G, Kozlov K, Kral J, Králik I, Kramer F, Kraus I, Krawutschke T, Kretz M, Krivda M, Krumbhorn D, Krus M, Kryshen E, Krzewicki M, Kucheriaev Y, Kuhn C, Kuijer PG, Kurashvili P, Kurepin A, Kurepin AB, Kuryakin A, Kushpil S, Kushpil V, Kweon MJ, Kwon Y, La Rocca P, Ladrón de Guevara P, Lafage V, Lara C, Larsen DT, Lazzeroni C, Le Bornec Y, Lea R, Lee KS, Lee SC, Lefèvre F, Lehnert J, Leistam L, Lenhardt M, Lenti V, León Monzón I, León Vargas H, Lévai P, Li X, Lietava R, Lindal S, Lindenstruth V, Lippmann C, Lisa MA, Liu L, Loggins VR, Loginov V, Lohn S, Lohner D, Loizides C, Lopez X, López Noriega M, López Torres E, Løvhøiden G, Lu XG, Luettig P, Lunardon M, Luparello G, Luquin L, Luzzi C, Ma K, Ma R, Madagodahettige-Don DM, Maevskaya A, Mager M, Mahapatra DP, Maire A, Malaev M, Maldonado Cervantes I, Mal'Kevich D, Malzacher P, Mamonov A, Manceau L, Mangotra L, Manko V, Manso F, Manzari V, Mao Y, Mareš J, Margagliotti GV, Margotti A, Marín A, Martashvili I, Martinengo P, Martínez MI, Martínez Davalos A, Martínez García G, Martynov Y, Mas A, Masciocchi S, Masera M, Masoni A, Massacrier L, Mastromarco M, Mastroserio A, Matthews ZL, Matyja A, Mayani D, Mazza G, Mazzoni MA, Meddi F, Menchaca-Rocha A, Mendez Lorenzo P, Mercado Pérez J, Mereu P, Miake Y, Midori J, Milano L, Milosevic J, Mischke A, Miśkowiec D, Mitu C, Mlynarz J, Mohanty B, Molnar L, Montaño Zetina L, Monteno M, Montes E, Morando M, Moreira De Godoy DA, Moretto S, Morsch A, Muccifora V, Mudnic E, Müller H, Muhuri S, Munhoz MG, Munoz J, Musa L, Musso A, Nandi BK, Nania R, Nappi E, Nattrass C, Navach F, Navin S, Nayak TK, Nazarenko S, Nazarov G, Nedosekin A, Nendaz F, Newby J, Nicassio M, Nielsen BS, Nikolaev S, Nikolic V, Nikulin S, Nikulin V, Nilsen BS, Nilsson MS, Noferini F, Nooren G, Novitzky N, Nyanin A, Nyatha A, Nygaard C, Nystrand J, Obayashi H, Ochirov A, Oeschler H, Oh SK, Oleniacz J, Oppedisano C, Ortiz Velasquez A, Ortona G, Oskarsson A, Ostrowski P, Otterlund I, Otwinowski J, Øvrebekk G, Oyama K, Ozawa K, Pachmayer Y, Pachr M, Padilla F, Pagano P, Paić G, Painke F, Pajares C, Pal S, Pal SK, Palaha A, Palmeri A, Pappalardo GS, Park WJ, Paticchio V, Pavlinov A, Pawlak T, Peitzmann T, Peresunko D, Pérez Lara CE, Perini D, Perrino D, Peryt W, Pesci A, Peskov V, Pestov Y, Peters AJ, Petráček V, Petris M, Petrov P, Petrovici M, Petta C, Piano S, Piccotti A, Pikna M, Pillot P, Pinazza O, Pinsky L, Pitz N, Piuz F, Piyarathna DB, Platt R, Płoskoń M, Pluta J, Pocheptsov T, Pochybova S, Podesta-Lerma PLM, Poghosyan MG, Polák K, Polichtchouk B, Pop A, Pospíšil V, Potukuchi B, Prasad SK, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puddu G, Pulvirenti A, Punin V, Putiš M, Putschke J, Quercigh E, Qvigstad H, Rachevski A, Rademakers A, Rademakers O, Radomski S, Räihä TS, Rak J, Rakotozafindrabe A, Ramello L, Ramírez Reyes A, Rammler M, Raniwala R, Raniwala S, Räsänen SS, Read KF, Real JS, Redlich K, Renfordt R, Reolon AR, Reshetin A, Rettig F, Revol JP, Reygers K, Ricaud H, Riccati L, Ricci RA, Richter M, Riedler P, Riegler W, Riggi F, Rivetti A, Rodríguez Cahuantzi M, Rohr D, Röhrich D, Romita R, Ronchetti F, Rosinský P, Rosnet P, Rossegger S, Rossi A, Roukoutakis F, Rousseau S, Roy C, Roy P, Rubio Montero AJ, Rui R, Rusanov I, Ryabinkin E, Rybicki A, Sadovsky S, Safařík K, Sahoo R, Sahu PK, Saiz P, Sakai S, Sakata D, Salgado CA, Samanta T, Sambyal S, Samsonov V, Sándor L, Sandoval A, Sano M, Sano S, Santo R, Santoro R, Sarkamo J, Saturnini P, Scapparone E, Scarlassara F, Scharenberg RP, Schiaua C, Schicker R, Schmidt C, Schmidt HR, Schreiner S, Schuchmann S, Schukraft J, Schutz Y, Schwarz K, Schweda K, Scioli G, Scomparin E, Scott PA, Scott R, Segato G, Senyukov S, Seo J, Serci S, Serradilla E, Sevcenco A, Shabratova G, Shahoyan R, Sharma N, Sharma S, Shigaki K, Shimomura M, Shtejer K, Sibiriak Y, Siciliano M, Sicking E, Siemiarczuk T, Silenzi A, Silvermyr D, Simonetti G, Singaraju R, Singh R, Sinha BC, Sinha T, Sitar B, Sitta M, Skaali TB, Skjerdal K, Smakal R, Smirnov N, Snellings R, Søgaard C, Soloviev A, Soltz R, Son H, Song M, Soos C, Soramel F, Spyropoulou-Stassinaki M, Srivastava BK, Stachel J, Stan I, Stefanek G, Stefanini G, Steinbeck T, Stenlund E, Steyn G, Stocco D, Stock R, Stolpovskiy M, Strmen P, Suaide AAP, Subieta Vásquez MA, Sugitate T, Suire C, Sumbera M, Susa T, Swoboda D, Symons TJM, Szanto de Toledo A, Szarka I, Szostak A, Tagridis C, Takahashi J, Tapia Takaki JD, Tauro A, Tavlet M, Tejeda Muñoz G, Telesca A, Terrevoli C, Thäder J, Thomas D, Thomas JH, Tieulent R, Timmins AR, Tlusty D, Toia A, Torii H, Toscano L, Tosello F, Traczyk T, Truesdale D, Trzaska WH, Tumkin A, Turrisi R, Turvey AJ, Tveter TS, Ulery J, Ullaland K, Uras A, Urbán J, Urciuoli GM, Usai GL, Vacchi A, Vala M, Valencia Palomo L, Vallero S, van der Kolk N, van Leeuwen M, Vande Vyvre P, Vannucci L, Vargas A, Varma R, Vasileiou M, Vasiliev A, Vechernin V, Venaruzzo M, Vercellin E, Vergara S, Vernet R, Verweij M, Vickovic L, Viesti G, Vikhlyantsev O, Vilakazi Z, Villalobos Baillie O, Vinogradov A, Vinogradov L, Vinogradov Y, Virgili T, Viyogi YP, Vodopyanov A, Voloshin K, Voloshin S, Volpe G, von Haller B, Vranic D, Vrláková J, Vulpescu B, Wagner B, Wagner V, Wan R, Wang D, Wang Y, Wang Y, Watanabe K, Wessels JP, Westerhoff U, Wiechula J, Wikne J, Wilde M, Wilk A, Wilk G, Williams MCS, Windelband B, Yang H, Yasnopolskiy S, Yi J, Yin Z, Yokoyama H, Yoo IK, Yuan X, Yushmanov I, Zabrodin E, Zampolli C, Zaporozhets S, Zarochentsev A, Závada P, Zbroszczyk H, Zelnicek P, Zenin A, Zgura I, Zhalov M, Zhang X, Zhou D, Zhu X, Zichichi A, Zinovjev G, Zoccarato Y, Zynovyev M. Centrality dependence of the charged-particle multiplicity density at midrapidity in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett 2011; 106:032301. [PMID: 21405267 DOI: 10.1103/physrevlett.106.032301] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2010] [Indexed: 05/30/2023]
Abstract
The centrality dependence of the charged-particle multiplicity density at midrapidity in Pb-Pb collisions at sqrt[s_{NN}]=2.76 TeV is presented. The charged-particle density normalized per participating nucleon pair increases by about a factor of 2 from peripheral (70%-80%) to central (0%-5%) collisions. The centrality dependence is found to be similar to that observed at lower collision energies. The data are compared with models based on different mechanisms for particle production in nuclear collisions.
Collapse
Affiliation(s)
- K Aamodt
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Aamodt K, Abelev B, Quintana AA, Adamová D, Adare AM, Aggarwal MM, Rinella GA, Agocs AG, Salazar SA, Ahammed Z, Masoodi AA, Ahmad N, Ahn SU, Akindinov A, Aleksandrov D, Alessandro B, Molina RA, Alici A, Alkin A, Aviña EA, Alt T, Altini V, Altinpinar S, Altsybeev I, Andrei C, Andronic A, Anguelov V, Anson C, Antičić T, Antinori F, Antonioli P, Aphecetche L, Appelshäuser H, Arbor N, Arcelli S, Arend A, Armesto N, Arnaldi R, Aronsson T, Arsene IC, Asryan A, Augustinus A, Averbeck R, Awes TC, Aystö J, Azmi MD, Bach M, Badalà A, Baek YW, Bagnasco S, Bailhache R, Bala R, Ferroli RB, Baldisseri A, Baldit A, Pedrosa FBDS, Bán J, Barbera R, Barile F, Barnaföldi GG, Barnby LS, Barret V, Bartke J, Basile M, Bastid N, Bathen B, Batigne G, Batyunya B, Baumann C, Bearden IG, Beck H, Belikov I, Bellini F, Bellwied R, Belmont-Moreno E, Beole S, Berceanu I, Bercuci A, Berdermann E, Berdnikov Y, Bergmann C, Betev L, Bhasin A, Bhati AK, Bianchi L, Bianchi N, Bianchin C, Bielčík J, Bielčíková J, Bilandzic A, Biolcati E, Blanc A, Blanco F, Blanco F, Blau D, Blume C, Boccioli M, Bock N, Bogdanov A, Bøggild H, Bogolyubsky M, Boldizsár L, Bombara M, Bombonati C, Book J, Borel H, Borissov A, Bortolin C, Bose S, Bossú F, Botje M, Böttger S, Boyer B, Braun-Munzinger P, Bravina L, Bregant M, Breitner T, Broz M, Brun R, Bruna E, Bruno GE, Budnikov D, Buesching H, Bugaiev K, Busch O, Buthelezi Z, Caffarri D, Cai X, Caines H, Villar EC, Camerini P, Canoa Roman V, Romeo GC, Carena F, Carena W, Carminati F, Díaz AC, Caselle M, Castellanos JC, Catanescu V, Cavicchioli C, Cepila J, Cerello P, Chang B, Chapeland S, Charvet JL, Chattopadhyay S, Chattopadhyay S, Cherney M, Cheshkov C, Cheynis B, Chiavassa E, Barroso VC, Chinellato DD, Chochula P, Chojnacki M, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Cicalo C, Cifarelli L, Cindolo F, Cleymans J, Coccetti F, Coffin JP, Coli S, Balbastre GC, del Valle ZC, Constantin P, Contin G, Contreras JG, Cormier TM, Morales YC, Maldonado IC, Cortese P, Cosentino MR, Costa F, Cotallo ME, Crescio E, Crochet P, Cuautle E, Cunqueiro L, Erasmo GD, Dainese A, Dalsgaard HH, Danu A, Das D, Das I, Das K, Dash A, Dash S, De S, Moregula ADA, de Barros GOV, De Caro A, de Cataldo G, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Pasquale S, De Remigis R, de Rooij R, Debski PR, Sanchez EDC, Delagrange H, Mercado YD, Dellacasa G, Deloff A, Demanov V, Dénes E, Deppman A, Di Bari D, Di Giglio C, Di Liberto S, Di Mauro A, Di Nezza P, Dietel T, Divià R, Djuvsland Ø, Dobrin A, Dobrowolski T, Domínguez I, Dönigus B, Dordic O, Driga O, Dubey AK, Dubuisson J, Ducroux L, Dupieux P, Majumdar AKD, Majumdar MRD, Elia D, Emschermann D, Engel H, Erdal HA, Espagnon B, Estienne M, Esumi S, Evans D, Evrard S, Eyyubova G, Fabjan CW, Fabris D, Faivre J, Falchieri D, Fantoni A, Fasel M, Fearick R, Fedunov A, Fehlker D, Fekete V, Felea D, Feofilov G, Téllez AF, Ferretti A, Ferretti R, Figiel J, Figueredo MAS, Filchagin S, Fini R, Finogeev D, Fionda FM, Fiore EM, Floris M, Foertsch S, Foka P, Fokin S, Fragiacomo E, Fragkiadakis M, Frankenfeld U, Fuchs U, Furano F, Furget C, Girard MF, Gaardhøje JJ, Gadrat S, Gagliardi M, Gago A, Gallio M, Gangadharan DR, Ganoti P, Ganti MS, Garabatos C, Garcia-Solis E, Garishvili I, Gemme R, Gerhard J, Germain M, Geuna C, Gheata A, Gheata M, Ghidini B, Ghosh P, Gianotti P, Girard MR, Giraudo G, Giubellino P, Gladysz-Dziadus E, Glässel P, Gomez R, Ferreiro EG, Santos HG, González-Trueba LH, González-Zamora P, Gorbunov S, Gotovac S, Grabski V, Grajcarek R, Grelli A, Grigoras A, Grigoras C, Grigoriev V, Grigoryan A, Grigoryan S, Grinyov B, Grion N, Gros P, Grosse-Oetringhaus JF, Grossiord JY, Grosso R, Guber F, Guernane R, Gutierrez CG, Guerzoni B, Gulbrandsen K, Gunji T, Gupta A, Gupta R, Gutbrod H, Haaland Ø, Hadjidakis C, Haiduc M, Hamagaki H, Hamar G, Harris JW, Hartig M, Hasch D, Hasegan D, Hatzifotiadou D, Hayrapetyan A, Heide M, Heinz M, Helstrup H, Herghelegiu A, Hernández C, Corral GH, Herrmann N, Hetland KF, Hicks B, Hille PT, Hippolyte B, Horaguchi T, Hori Y, Hristov P, Hřivnáčová I, Huang M, Huber S, Humanic TJ, Hwang DS, Ichou R, Ilkaev R, Ilkiv I, Inaba M, Incani E, Innocenti GM, Innocenti PG, Ippolitov M, Irfan M, Ivan C, Ivanov A, Ivanov M, Ivanov V, Jachołkowski A, Jacobs PM, Jancurová L, Jangal S, Janik R, Jena S, Jirden L, Jones GT, Jones PG, Jovanović P, Jung H, Jung W, Jusko A, Kalcher S, Kaliňák P, Kalisky M, Kalliokoski T, Kalweit A, Kamermans R, Kanaki K, Kang E, Kang JH, Kaplin V, Karavichev O, Karavicheva T, Karpechev E, Kazantsev A, Kebschull U, Keidel R, Khan MM, Khan SA, Khanzadeev A, Kharlov Y, Kileng B, Kim DJ, Kim DS, Kim DW, Kim HN, Kim JH, Kim JS, Kim M, Kim M, Kim S, Kim SH, Kirsch S, Kisel I, Kiselev S, Kisiel A, Klay JL, Klein J, Klein-Bösing C, Kliemant M, Klovning A, Kluge A, Knichel ML, Koch K, Köhler MK, Kolevatov R, Kolojvari A, Kondratiev V, Kondratyeva N, Konevskih A, Kornaś E, Don CKK, Kour R, Kowalski M, Kox S, Meethaleveedu GK, Kozlov K, Kral J, Králik I, Kramer F, Kraus I, Krawutschke T, Kretz M, Krivda M, Krizek F, Krumbhorn D, Krus M, Kryshen E, Krzewicki M, Kucheriaev Y, Kuhn C, Kuijer PG, Kurashvili P, Kurepin A, Kurepin AB, Kuryakin A, Kushpil S, Kushpil V, Kweon MJ, Kwon Y, La Rocca P, Ladrón de Guevara P, Lafage V, Lara C, Lardeux A, Larsen DT, Lazzeroni C, Le Bornec Y, Lea R, Lee KS, Lee SC, Lefèvre F, Lehnert J, Leistam L, Lenhardt M, Lenti V, Monzón IL, Vargas HL, Lévai P, Li X, Lien J, Lietava R, Lindal S, Lindenstruth V, Lippmann C, Lisa MA, Liu L, Loenne PI, Loggins VR, Loginov V, Lohn S, Loizides C, Loo KK, Lopez X, Noriega ML, Torres EL, Løvhøiden G, Lu XG, Luettig P, Lunardon M, Luparello G, Luquin L, Luzzi C, Ma K, Ma R, Madagodahettige-Don DM, Maevskaya A, Mager M, Mahapatra DP, Maire A, Mal'Kevich D, Malaev M, Cervantes IM, Malinina L, Malzacher P, Mamonov A, Manceau L, Mangotra L, Manko V, Manso F, Manzari V, Mao Y, Mareš J, Margagliotti GV, Margotti A, Marín A, Markert C, Martashvili I, Martinengo P, Martínez MI, Davalos AM, García GM, Martynov Y, Masciocchi S, Masera M, Masoni A, Massacrier L, Mastromarco M, Mastroserio A, Matthews ZL, Matyja A, Mayani D, Mayer C, Mazza G, Mazzoni MA, Meddi F, Menchaca-Rocha A, Lorenzo PM, Menis I, Pérez JM, Meres M, Mereu P, Miake Y, Midori J, Milano L, Milosevic J, Mischke A, Miśkowiec D, Mitu C, Mlynarz J, Mohanty AK, Mohanty B, Molnar L, Zetina LM, Monteno M, Montes E, Morando M, De Godoy DAM, Moretto S, Morsch A, Muccifora V, Mudnic E, Muhuri S, Müller H, Munhoz MG, Munoz J, Musa L, Musso A, Nandi BK, Nania R, Nappi E, Nattrass C, Navach F, Navin S, Nayak TK, Nazarenko S, Nazarov G, Nedosekin A, Nendaz F, Newby J, Nicassio M, Nielsen BS, Niida T, Nikolaev S, Nikolic V, Nikulin S, Nikulin V, Nilsen BS, Nilsson MS, Noferini F, Nooren G, Novitzky N, Nyanin A, Nyatha A, Nygaard C, Nystrand J, Obayashi H, Ochirov A, Oeschler H, Oh SK, Oleniacz J, Oppedisano C, Velasquez AO, Ortona G, Oskarsson A, Ostrowski P, Otterlund I, Otwinowski J, Oyama K, Ozawa K, Pachmayer Y, Pachr M, Padilla F, Pagano P, Jayarathna SP, Paić G, Painke F, Pajares C, Pal S, Pal SK, Palaha A, Palmeri A, Pappalardo GS, Park WJ, Patalakha DI, Paticchio V, Pavlinov A, Pawlak T, Peitzmann T, Peresunko D, Lara CEP, Perini D, Perrino D, Peryt W, Pesci A, Peskov V, Pestov Y, Peters AJ, Petráček V, Petran M, Petris M, Petrov P, Petrovici M, Petta C, Piano S, Piccotti A, Pikna M, Pillot P, Pinazza O, Pinsky L, Pitz N, Piuz F, Piyarathna DB, Platt R, Płoskoń M, Pluta J, Pocheptsov T, Pochybova S, Podesta-Lerma PLM, Poghosyan MG, Polák K, Polichtchouk B, Pop A, Porteboeuf S, Pospíšil V, Potukuchi B, Prasad SK, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puddu G, Pulvirenti A, Punin V, Putiš M, Putschke J, Quercigh E, Qvigstad H, Rachevski A, Rademakers A, Rademakers O, Radomski S, Räihä TS, Rak J, Rakotozafindrabe A, Ramello L, Reyes AR, Rammler M, Raniwala R, Raniwala S, Räsänen SS, Read KF, Real J, Redlich K, Renfordt R, Reolon AR, Reshetin A, Rettig F, Revol JP, Reygers K, Ricaud H, Riccati L, Ricci RA, Richter M, Riedler P, Riegler W, Riggi F, Cahuantzi MR, Rohr D, Röhrich D, Romita R, Ronchetti F, Rosinský P, Rosnet P, Rossegger S, Rossi A, Roukoutakis F, Rousseau S, Roy C, Roy P, Montero AJR, Rui R, Rivetti A, Rusanov I, Ryabinkin E, Rybicki A, Sadovsky S, Safařík K, Sahoo R, Sahu PK, Saini J, Saiz P, Sakai S, Sakata D, Salgado CA, Samanta T, Sambyal S, Samsonov V, Castro XS, Sándor L, Sandoval A, Sano M, Sano S, Santo R, Santoro R, Sarkamo J, Saturnini P, Scapparone E, Scarlassara F, Scharenberg RP, Schiaua C, Schicker R, Schmidt C, Schmidt HR, Schreiner S, Schuchmann S, Schukraft J, Schutz Y, Schwarz K, Schweda K, Scioli G, Scomparin E, Scott PA, Scott R, Segato G, Selyuzhenkov I, Senyukov S, Seo J, Serci S, Serradilla E, Sevcenco A, Sgura I, Shabratova G, Shahoyan R, Sharma N, Sharma S, Shigaki K, Shimomura M, Shtejer K, Sibiriak Y, Siciliano M, Sicking E, Siemiarczuk T, Silenzi A, Silvermyr D, Simonetti G, Singaraju R, Singh R, Singhal V, Sinha BC, Sinha T, Sitar B, Sitta M, Skaali TB, Skjerdal K, Smakal R, Smirnov N, Snellings R, Søgaard C, Soloviev A, Soltz R, Son H, Song J, Song M, Soos C, Soramel F, Spyropoulou-Stassinaki M, Srivastava BK, Stachel J, Stan I, Stefanek G, Stefanini G, Steinbeck T, Steinpreis M, Stenlund E, Steyn G, Stocco D, Stock R, Stokkevag CH, Stolpovskiy M, Strmen P, Suaide AAP, Vásquez MAS, Sugitate T, Suire C, Sukhorukov M, Sumbera M, Susa T, Swoboda D, Symons TJM, de Toledo AS, Szarka I, Szostak A, Tagridis C, Takahashi J, Takaki JDT, Tauro A, Tavlet M, Muñoz GT, Telesca A, Terrevoli C, Thäder J, Thomas D, Thomas JH, Tieulent R, Timmins AR, Tlusty D, Toia A, Torii H, Toscano L, Tosello F, Traczyk T, Truesdale D, Trzaska WH, Tsuji T, Tumkin A, Turrisi R, Turvey AJ, Tveter TS, Ulery J, Ullaland K, Uras A, Urbán J, Urciuoli GM, Usai GL, Vacchi A, Vajzer M, Vala M, Palomo LV, Vallero S, van der Kolk N, van Leeuwen M, Vande Vyvre P, Vannucci L, Vargas A, Varma R, Vasileiou M, Vasiliev A, Vechernin V, Veldhoen M, Venaruzzo M, Vercellin E, Vergara S, Vernekohl DC, Vernet R, Verweij M, Vickovic L, Viesti G, Vikhlyantsev O, Vilakazi Z, Baillie OV, Vinogradov A, Vinogradov L, Vinogradov Y, Virgili T, Viyogi YP, Vodopyanov A, Voloshin K, Voloshin S, Volpe G, von Haller B, Vranic D, Øvrebekk G, Vrláková J, Vulpescu B, Vyushin A, Wagner B, Wagner V, Wan R, Wang D, Wang Y, Wang Y, Watanabe K, Wessels JP, Westerhoff U, Wiechula J, Wikne J, Wilde M, Wilk A, Wilk G, Williams MCS, Windelband B, Karampatsos LX, Yang H, Yang S, Yasnopolskiy S, Yi J, Yin Z, Yokoyama H, Yoo IK, Yu W, Yuan X, Yushmanov I, Zabrodin E, Zach C, Zampolli C, Zaporozhets S, Zarochentsev A, Závada P, Zaviyalov N, Zbroszczyk H, Zelnicek P, Zenin A, Zgura I, Zhalov M, Zhang X, Zhou D, Zichichi A, Zinovjev G, Zoccarato Y, Zynovyev M. Elliptic flow of charged particles in Pb-Pb collisions at sqrt[S(NN)] = 2.76 TeV. Phys Rev Lett 2010; 105:252302. [PMID: 21231580 DOI: 10.1103/physrevlett.105.252302] [Citation(s) in RCA: 84] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/18/2010] [Indexed: 05/30/2023]
Abstract
We report the first measurement of charged particle elliptic flow in Pb-Pb collisions at sqrt[S(NN)] =2.76 TeV with the ALICE detector at the CERN Large Hadron Collider. The measurement is performed in the central pseudorapidity region (|η|<0.8) and transverse momentum range 0.2<p t<5.0 GeV/c. The elliptic flow signal v₂, measured using the 4-particle correlation method, averaged over transverse momentum and pseudorapidity is 0.087 ± 0.002(stat) ± 0.003(syst) in the 40%-50% centrality class. The differential elliptic flow v₂ p t reaches a maximum of 0.2 near p t =3 GeV/c. Compared to RHIC Au-Au collisions at sqrt[S(NN)] 200 GeV, the elliptic flow increases by about 30%. Some hydrodynamic model predictions which include viscous corrections are in agreement with the observed increase.
Collapse
Affiliation(s)
- K Aamodt
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Aamodt K, Abelev B, Quintana AA, Adamová D, Adare AM, Aggarwal MM, Rinella GA, Agocs AG, Salazar SA, Ahammed Z, Masoodi AA, Ahmad N, Ahn SU, Akindinov A, Aleksandrov D, Alessandro B, Molina RA, Alici A, Alkin A, Aviña EA, Alt T, Altini V, Altinpinar S, Altsybeev I, Andrei C, Andronic A, Anguelov V, Anson C, Antičić T, Antinori F, Antonioli P, Aphecetche L, Appelshäuser H, Arbor N, Arcelli S, Arend A, Armesto N, Arnaldi R, Aronsson T, Arsene IC, Asryan A, Augustinus A, Averbeck R, Awes TC, Aystö J, Azmi MD, Bach M, Badalà A, Baek YW, Bagnasco S, Bailhache R, Bala R, Ferroli RB, Baldisseri A, Baldit A, Pedrosa FBDS, Bán J, Barbera R, Barile F, Barnaföldi GG, Barnby LS, Barret V, Bartke J, Basile M, Bastid N, Bathen B, Batigne G, Batyunya B, Baumann C, Bearden IG, Beck H, Belikov I, Bellini F, Bellwied R, Belmont-Moreno E, Beole S, Berceanu I, Bercuci A, Berdermann E, Berdnikov Y, Bergmann C, Betev L, Bhasin A, Bhati AK, Bianchi L, Bianchi N, Bianchin C, Bielčík J, Bielčíková J, Bilandzic A, Biolcati E, Blanc A, Blanco F, Blanco F, Blau D, Blume C, Boccioli M, Bock N, Bogdanov A, Bøggild H, Bogolyubsky M, Boldizsár L, Bombara M, Bombonati C, Book J, Borel H, Borissov A, Bortolin C, Bose S, Bossú F, Botje M, Böttger S, Boyer B, Braun-Munzinger P, Bravina L, Bregant M, Breitner T, Broz M, Brun R, Bruna E, Bruno GE, Budnikov D, Buesching H, Bugaiev K, Busch O, Buthelezi Z, Caffarri D, Cai X, Caines H, Villar EC, Camerini P, Roman VC, Romeo GC, Carena F, Carena W, Carminati F, Díaz AC, Caselle M, Castellanos JC, Catanescu V, Cavicchioli C, Cepila J, Cerello P, Chang B, Chapeland S, Charvet JL, Chattopadhyay S, Chattopadhyay S, Cherney M, Cheshkov C, Cheynis B, Chiavassa E, Barroso VC, Chinellato DD, Chochula P, Chojnacki M, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Cicalo C, Cifarelli L, Cindolo F, Cleymans J, Coccetti F, Coffin JP, Coli S, Balbastre GC, Del Valle ZC, Constantin P, Contin G, Contreras JG, Cormier TM, Morales YC, Maldonado IC, Cortese P, Cosentino MR, Costa F, Cotallo ME, Crescio E, Crochet P, Cuautle E, Cunqueiro L, Erasmo GD, Dainese A, Dalsgaard HH, Danu A, Das D, Das I, Das K, Dash A, Dash S, De S, Moregula ADA, de Barros GOV, De Caro A, de Cataldo G, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Pasquale S, De Remigis R, de Rooij R, Debski PR, Sanchez EDC, Delagrange H, Mercado YD, Dellacasa G, Deloff A, Demanov V, Dénes E, Deppman A, Di Bari D, Di Giglio C, Di Liberto S, Di Mauro A, Di Nezza P, Dietel T, Divià R, Djuvsland Ø, Dobrin A, Dobrowolski T, Domínguez I, Dönigus B, Dordic O, Driga O, Dubey AK, Dubuisson J, Ducroux L, Dupieux P, Majumdar AKD, Majumdar MRD, Elia D, Emschermann D, Engel H, Erdal HA, Espagnon B, Estienne M, Esumi S, Evans D, Evrard S, Eyyubova G, Fabjan CW, Fabris D, Faivre J, Falchieri D, Fantoni A, Fasel M, Fearick R, Fedunov A, Fehlker D, Fekete V, Felea D, Feofilov G, Téllez AF, Ferretti A, Ferretti R, Figiel J, Figueredo MAS, Filchagin S, Fini R, Finogeev D, Fionda FM, Fiore EM, Floris M, Foertsch S, Foka P, Fokin S, Fragiacomo E, Fragkiadakis M, Frankenfeld U, Fuchs U, Furano F, Furget C, Girard MF, Gaardhøje JJ, Gadrat S, Gagliardi M, Gago A, Gallio M, Gangadharan DR, Ganoti P, Ganti MS, Garabatos C, Garcia-Solis E, Garishvili I, Gemme R, Gerhard J, Germain M, Geuna C, Gheata A, Gheata M, Ghidini B, Ghosh P, Gianotti P, Girard MR, Giraudo G, Giubellino P, Gladysz-Dziadus E, Glässel P, Gomez R, Ferreiro EG, Santos HG, González-Trueba LH, González-Zamora P, Gorbunov S, Gotovac S, Grabski V, Grajcarek R, Grelli A, Grigoras A, Grigoras C, Grigoriev V, Grigoryan A, Grigoryan S, Grinyov B, Grion N, Gros P, Grosse-Oetringhaus JF, Grossiord JY, Grosso R, Guber F, Guernane R, Gutierrez CG, Guerzoni B, Gulbrandsen K, Gunji T, Gupta A, Gupta R, Gutbrod H, Haaland Ø, Hadjidakis C, Haiduc M, Hamagaki H, Hamar G, Harris JW, Hartig M, Hasch D, Hasegan D, Hatzifotiadou D, Hayrapetyan A, Heide M, Heinz M, Helstrup H, Herghelegiu A, Hernández C, Corral GH, Herrmann N, Hetland KF, Hicks B, Hille PT, Hippolyte B, Horaguchi T, Hori Y, Hristov P, Hřivnáčová I, Huang M, Huber S, Humanic TJ, Hwang DS, Ichou R, Ilkaev R, Ilkiv I, Inaba M, Incani E, Innocenti GM, Innocenti PG, Ippolitov M, Irfan M, Ivan C, Ivanov A, Ivanov M, Ivanov V, Jachołkowski A, Jacobs PM, Jancurová L, Jangal S, Janik R, Jena S, Jirden L, Jones GT, Jones PG, Jovanović P, Jung H, Jung W, Jusko A, Kalcher S, Kaliňák P, Kalisky M, Kalliokoski T, Kalweit A, Kamermans R, Kanaki K, Kang E, Kang JH, Kaplin V, Karavichev O, Karavicheva T, Karpechev E, Kazantsev A, Kebschull U, Keidel R, Khan MM, Khan SA, Khanzadeev A, Kharlov Y, Kileng B, Kim DJ, Kim DS, Kim DW, Kim HN, Kim JH, Kim JS, Kim M, Kim M, Kim S, Kim SH, Kirsch S, Kisel I, Kiselev S, Kisiel A, Klay JL, Klein J, Klein-Bösing C, Kliemant M, Klovning A, Kluge A, Knichel ML, Koch K, Köhler MK, Kolevatov R, Kolojvari A, Kondratiev V, Kondratyeva N, Konevskih A, Kornaś E, Don CKK, Kour R, Kowalski M, Kox S, Meethaleveedu GK, Kozlov K, Kral J, Králik I, Kramer F, Kraus I, Krawutschke T, Kretz M, Krivda M, Krizek F, Krumbhorn D, Krus M, Kryshen E, Krzewicki M, Kucheriaev Y, Kuhn C, Kuijer PG, Kurashvili P, Kurepin A, Kurepin AB, Kuryakin A, Kushpil S, Kushpil V, Kweon MJ, Kwon Y, La Rocca P, de Guevara PL, Lafage V, Lara C, Lardeux A, Larsen DT, Lazzeroni C, Le Bornec Y, Lea R, Lee KS, Lee SC, Lefèvre F, Lehnert J, Leistam L, Lenhardt M, Lenti V, Monzón IL, Vargas HL, Lévai P, Li X, Lien J, Lietava R, Lindal S, Lindenstruth V, Lippmann C, Lisa MA, Liu L, Loenne PI, Loggins VR, Loginov V, Lohn S, Loizides C, Loo KK, Lopez X, Noriega ML, Torres EL, Løvhøiden G, Lu XG, Luettig P, Lunardon M, Luparello G, Luquin L, Luzzi C, Ma K, Ma R, Madagodahettige-Don DM, Maevskaya A, Mager M, Mahapatra DP, Maire A, Mal'Kevich D, Malaev M, Cervantes IM, Malinina L, Malzacher P, Mamonov A, Manceau L, Mangotra L, Manko V, Manso F, Manzari V, Mao Y, Mareš J, Margagliotti GV, Margotti A, Marín A, Markert C, Martashvili I, Martinengo P, Martínez MI, Davalos AM, García GM, Martynov Y, Masciocchi S, Masera M, Masoni A, Massacrier L, Mastromarco M, Mastroserio A, Matthews ZL, Matyja A, Mayani D, Mayer C, Mazza G, Mazzoni MA, Meddi F, Menchaca-Rocha A, Lorenzo PM, Menis I, Pérez JM, Meres M, Mereu P, Miake Y, Midori J, Milano L, Milosevic J, Mischke A, Miśkowiec D, Mitu C, Mlynarz J, Mohanty AK, Mohanty B, Molnar L, Zetina LM, Monteno M, Montes E, Morando M, De Godoy DAM, Moretto S, Morsch A, Muccifora V, Mudnic E, Muhuri S, Müller H, Munhoz MG, Munoz J, Musa L, Musso A, Nandi BK, Nania R, Nappi E, Nattrass C, Navach F, Navin S, Nayak TK, Nazarenko S, Nazarov G, Nedosekin A, Nendaz F, Newby J, Nicassio M, Nielsen BS, Niida T, Nikolaev S, Nikolic V, Nikulin S, Nikulin V, Nilsen BS, Nilsson MS, Noferini F, Nooren G, Novitzky N, Nyanin A, Nyatha A, Nygaard C, Nystrand J, Obayashi H, Ochirov A, Oeschler H, Oh SK, Oleniacz J, Oppedisano C, Velasquez AO, Ortona G, Oskarsson A, Ostrowski P, Otterlund I, Otwinowski J, Oyama K, Ozawa K, Pachmayer Y, Pachr M, Padilla F, Pagano P, Jayarathna SP, Paić G, Painke F, Pajares C, Pal S, Pal SK, Palaha A, Palmeri A, Pappalardo GS, Park WJ, Patalakha DI, Paticchio V, Pavlinov A, Pawlak T, Peitzmann T, Peresunko D, Lara CEP, Perini D, Perrino D, Peryt W, Pesci A, Peskov V, Pestov Y, Peters AJ, Petráček V, Petran M, Petris M, Petrov P, Petrovici M, Petta C, Piano S, Piccotti A, Pikna M, Pillot P, Pinazza O, Pinsky L, Pitz N, Piuz F, Piyarathna DB, Platt R, Płoskoń M, Pluta J, Pocheptsov T, Pochybova S, Podesta-Lerma PLM, Poghosyan MG, Polák K, Polichtchouk B, Pop A, Porteboeuf S, Pospíšil V, Potukuchi B, Prasad SK, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puddu G, Pulvirenti A, Punin V, Putiš M, Putschke J, Quercigh E, Qvigstad H, Rachevski A, Rademakers A, Rademakers O, Radomski S, Räihä TS, Rak J, Rakotozafindrabe A, Ramello L, Ramírez Reyes A, Rammler M, Raniwala R, Raniwala S, Räsänen SS, Read KF, Real J, Redlich K, Renfordt R, Reolon AR, Reshetin A, Rettig F, Revol JP, Reygers K, Ricaud H, Riccati L, Ricci RA, Richter M, Riedler P, Riegler W, Riggi F, Cahuantzi MR, Rohr D, Röhrich D, Romita R, Ronchetti F, Rosinský P, Rosnet P, Rossegger S, Rossi A, Roukoutakis F, Rousseau S, Roy C, Roy P, Montero AJR, Rui R, Rivetti A, Rusanov I, Ryabinkin E, Rybicki A, Sadovsky S, Safařík K, Sahoo R, Sahu PK, Saini J, Saiz P, Sakai S, Sakata D, Salgado CA, Samanta T, Sambyal S, Samsonov V, Castro XS, Sándor L, Sandoval A, Sano M, Sano S, Santo R, Santoro R, Sarkamo J, Saturnini P, Scapparone E, Scarlassara F, Scharenberg RP, Schiaua C, Schicker R, Schmidt C, Schmidt HR, Schreiner S, Schuchmann S, Schukraft J, Schutz Y, Schwarz K, Schweda K, Scioli G, Scomparin E, Scott PA, Scott R, Segato G, Selyuzhenkov I, Senyukov S, Seo J, Serci S, Serradilla E, Sevcenco A, Sgura I, Shabratova G, Shahoyan R, Sharma N, Sharma S, Shigaki K, Shimomura M, Shtejer K, Sibiriak Y, Siciliano M, Sicking E, Siemiarczuk T, Silenzi A, Silvermyr D, Simonetti G, Singaraju R, Singh R, Singhal V, Sinha BC, Sinha T, Sitar B, Sitta M, Skaali TB, Skjerdal K, Smakal R, Smirnov N, Snellings R, Søgaard C, Soloviev A, Soltz R, Son H, Song J, Song M, Soos C, Soramel F, Spyropoulou-Stassinaki M, Srivastava BK, Stachel J, Stan I, Stefanek G, Stefanini G, Steinbeck T, Steinpreis M, Stenlund E, Steyn G, Stocco D, Stock R, Stokkevag CH, Stolpovskiy M, Strmen P, Suaide AAP, Vásquez MAS, Sugitate T, Suire C, Sukhorukov M, Sumbera M, Susa T, Swoboda D, Symons TJM, de Toledo AS, Szarka I, Szostak A, Tagridis C, Takahashi J, Takaki JDT, Tauro A, Tavlet M, Muñoz GT, Telesca A, Terrevoli C, Thäder J, Thomas D, Thomas JH, Tieulent R, Timmins AR, Tlusty D, Toia A, Torii H, Toscano L, Tosello F, Traczyk T, Truesdale D, Trzaska WH, Tsuji T, Tumkin A, Turrisi R, Turvey AJ, Tveter TS, Ulery J, Ullaland K, Uras A, Urbán J, Urciuoli GM, Usai GL, Vacchi A, Vajzer M, Vala M, Palomo LV, Vallero S, van der Kolk N, van Leeuwen M, Vande Vyvre P, Vannucci L, Vargas A, Varma R, Vasileiou M, Vasiliev A, Vechernin V, Veldhoen M, Venaruzzo M, Vercellin E, Vergara S, Vernekohl DC, Vernet R, Verweij M, Vickovic L, Viesti G, Vikhlyantsev O, Vilakazi Z, Baillie OV, Vinogradov A, Vinogradov L, Vinogradov Y, Virgili T, Viyogi YP, Vodopyanov A, Voloshin K, Voloshin S, Volpe G, von Haller B, Vranic D, Øvrebekk G, Vrláková J, Vulpescu B, Vyushin A, Wagner B, Wagner V, Wan R, Wang D, Wang Y, Wang Y, Watanabe K, Wessels JP, Westerhoff U, Wiechula J, Wikne J, Wilde M, Wilk A, Wilk G, Williams MCS, Windelband B, Karampatsos LX, Yang H, Yang S, Yasnopolskiy S, Yi J, Yin Z, Yokoyama H, Yoo IK, Yu W, Yuan X, Yushmanov I, Zabrodin E, Zach C, Zampolli C, Zaporozhets S, Zarochentsev A, Závada P, Zaviyalov N, Zbroszczyk H, Zelnicek P, Zenin A, Zgura I, Zhalov M, Zhang X, Zhou D, Zichichi A, Zinovjev G, Zoccarato Y, Zynovyev M. Charged-particle multiplicity density at midrapidity in central Pb-Pb collisions at sqrt[S(NN)] = 2.76 TeV. Phys Rev Lett 2010; 105:252301. [PMID: 21231579 DOI: 10.1103/physrevlett.105.252301] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/19/2010] [Indexed: 05/30/2023]
Abstract
The first measurement of the charged-particle multiplicity density at midrapidity in Pb-Pb collisions at a center-of-mass energy per nucleon pair √ S NN = 2.76 TeV is presented. For an event sample corresponding to the most central 5% of the hadronic cross section, the pseudorapidity density of primary charged particles at midrapidity is 1584 ± 4(stat) ± 76(syst), which corresponds to 8.3 ± 0.4(syst) per participating nucleon pair. This represents an increase of about a factor 1.9 relative to pp collisions at similar collision energies, and about a factor 2.2 to central Au-Au collisions at √ S NN = 2.76 TeV. This measurement provides the first experimental constraint for models of nucleus-nucleus collisions at LHC energies.
Collapse
Affiliation(s)
- K Aamodt
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Park JY, Kwon YC, Lee KH, Kim HN, Lee KY, Kim DM. Screening of optimal ribosome binding sites (RBSs) for high-level protein expression in a cell-free protein synthesis system derived from Streptomyces venezuelae. J Biotechnol 2010. [DOI: 10.1016/j.jbiotec.2010.09.853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
39
|
Lee KY, Kwon YC, Lee KH, Byun JY, Kim HN, Kim DM. A cell-free protein synthesis system derived from the extract of Streptomyces venezuelae. J Biotechnol 2010. [DOI: 10.1016/j.jbiotec.2010.09.852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
40
|
Aamodt K, Abel N, Abeysekara U, Abrahantes Quintana A, Abramyan A, Adamová D, Aggarwal MM, Aglieri Rinella G, Agocs AG, Aguilar Salazar S, Ahammed Z, Ahmad A, Ahmad N, Ahn SU, Akimoto R, Akindinov A, Aleksandrov D, Alessandro B, Alfaro Molina R, Alici A, Almaráz Aviña E, Alme J, Alt T, Altini V, Altinpinar S, Andrei C, Andronic A, Anelli G, Angelov V, Anson C, Anticić T, Antinori F, Antinori S, Antipin K, Antończyk D, Antonioli P, Anzo A, Aphecetche L, Appelshäuser H, Arcelli S, Arceo R, Arend A, Armesto N, Arnaldi R, Aronsson T, Arsene IC, Asryan A, Augustinus A, Averbeck R, Awes TC, Aystö J, Azmi MD, Bablok S, Bach M, Badalà A, Baek YW, Bagnasco S, Bailhache R, Bala R, Baldisseri A, Baldit A, Bán J, Barbera R, Barnaföldi GG, Barnby LS, Barret V, Bartke J, Barile F, Basile M, Basmanov V, Bastid N, Bathen B, Batigne G, Batyunya B, Baumann C, Bearden IG, Becker B, Belikov I, Bellwied R, Belmont-Moreno E, Belogianni A, Benhabib L, Beole S, Berceanu I, Bercuci A, Berdermann E, Berdnikov Y, Betev L, Bhasin A, Bhati AK, Bianchi L, Bianchi N, Bianchin C, Bielcík J, Bielcíková J, Bilandzic A, Bimbot L, Biolcati E, Blanc A, Blanco F, Blanco F, Blau D, Blume C, Boccioli M, Bock N, Bogdanov A, Bøggild H, Bogolyubsky M, Bohm J, Boldizsár L, Bombara M, Bombonati C, Bondila M, Borel H, Borisov A, Bortolin C, Bose S, Bosisio L, Bossú F, Botje M, Böttger S, Bourdaud G, Boyer B, Braun M, Braun-Munzinger P, Bravina L, Bregant M, Breitner T, Bruckner G, Brun R, Bruna E, Bruno GE, Budnikov D, Buesching H, Buncic P, Busch O, Buthelezi Z, Caffarri D, Cai X, Caines H, Calvo E, Camacho E, Camerini P, Campbell M, Canoa Roman V, Capitani GP, Cara Romeo G, Carena F, Carena W, Carminati F, Casanova Díaz A, Caselle M, Castillo Castellanos J, Castillo Hernandez JF, Catanescu V, Cattaruzza E, Cavicchioli C, Cerello P, Chambert V, Chang B, Chapeland S, Charpy A, Charvet JL, Chattopadhyay S, Chattopadhyay S, Cherney M, Cheshkov C, Cheynis B, Chiavassa E, Chibante Barroso V, Chinellato DD, Chochula P, Choi K, Chojnacki M, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Chuman F, Cicalo C, Cifarelli L, Cindolo F, Cleymans J, Cobanoglu O, Coffin JP, Coli S, Colla A, Conesa Balbastre G, Conesa Del Valle Z, Conner ES, Constantin P, Contin G, Contreras JG, Corrales Morales Y, Cormier TM, Cortese P, Cortés Maldonado I, Cosentino MR, Costa F, Cotallo ME, Crescio E, Crochet P, Cuautle E, Cunqueiro L, Cussonneau J, Dainese A, Dalsgaard HH, Danu A, Das I, Dash A, Dash S, de Barros GOV, De Caro A, de Cataldo G, de Cuveland J, De Falco A, De Gaspari M, de Groot J, De Gruttola D, De Marco N, De Pasquale S, De Remigis R, de Rooij R, de Vaux G, Delagrange H, Delgado Y, Dellacasa G, Deloff A, Demanov V, Dénes E, Deppman A, D'Erasmo G, Derkach D, Devaux A, Di Bari D, Di Giglio C, Di Liberto S, Di Mauro A, Di Nezza P, Dialinas M, Díaz L, Díaz R, Dietel T, Divià R, Djuvsland O, Dobretsov V, Dobrin A, Dobrowolski T, Dönigus B, Domínguez I, Don DMM, Dordic O, Dubey AK, Dubuisson J, Ducroux L, Dupieux P, Dutta Majumdar AK, Dutta Majumdar MR, Elia D, Emschermann D, Enokizono A, Espagnon B, Estienne M, Esumi S, Evans D, Evrard S, Eyyubova G, Fabjan CW, Fabris D, Faivre J, Falchieri D, Fantoni A, Fasel M, Fateev O, Fearick R, Fedunov A, Fehlker D, Fekete V, Felea D, Fenton-Olsen B, Feofilov G, Fernández Téllez A, Ferreiro EG, Ferretti A, Ferretti R, Figueredo MAS, Filchagin S, Fini R, Fionda FM, Fiore EM, Floris M, Fodor Z, Foertsch S, Foka P, Fokin S, Formenti F, Fragiacomo E, Fragkiadakis M, Frankenfeld U, Frolov A, Fuchs U, Furano F, Furget C, Fusco Girard M, Gaardhøje JJ, Gadrat S, Gagliardi M, Gago A, Gallio M, Ganoti P, Ganti MS, Garabatos C, García Trapaga C, Gebelein J, Gemme R, Germain M, Gheata A, Gheata M, Ghidini B, Ghosh P, Giraudo G, Giubellino P, Gladysz-Dziadus E, Glasow R, Glässel P, Glenn A, Gómez Jiménez R, González Santos H, González-Trueba LH, González-Zamora P, Gorbunov S, Gorbunov Y, Gotovac S, Gottschlag H, Grabski V, Grajcarek R, Grelli A, Grigoras A, Grigoras C, Grigoriev V, Grigoryan A, Grigoryan S, Grinyov B, Grion N, Gros P, Grosse-Oetringhaus JF, Grossiord JY, Grosso R, Guber F, Guernane R, Guerra C, Guerzoni B, Gulbrandsen K, Gulkanyan H, Gunji T, Gupta A, Gupta R, Gustafsson HA, Gutbrod H, Haaland O, Hadjidakis C, Haiduc M, Hamagaki H, Hamar G, Hamblen J, Han BH, Harris JW, Hartig M, Harutyunyan A, Hasch D, Hasegan D, Hatzifotiadou D, Hayrapetyan A, Heide M, Heinz M, Helstrup H, Herghelegiu A, Hernández C, Herrera Corral G, Herrmann N, Hetland KF, Hicks B, Hiei A, Hille PT, Hippolyte B, Horaguchi T, Hori Y, Hristov P, Hrivnácová I, Hu S, Huang M, Huber S, Humanic TJ, Hutter D, Hwang DS, Ichou R, Ilkaev R, Ilkiv I, Inaba M, Innocenti PG, Ippolitov M, Irfan M, Ivan C, Ivanov A, Ivanov M, Ivanov V, Iwasaki T, Jachołkowski A, Jacobs P, Jancurová L, Jangal S, Janik R, Jena C, Jena S, Jirden L, Jones GT, Jones PG, Jovanović P, Jung H, Jung W, Jusko A, Kaidalov AB, Kalcher S, Kalinák P, Kalisky M, Kalliokoski T, Kalweit A, Kamal A, Kamermans R, Kanaki K, Kang E, Kang JH, Kapitan J, Kaplin V, Kapusta S, Karavichev O, Karavicheva T, Karpechev E, Kazantsev A, Kebschull U, Keidel R, Khan MM, Khan SA, Khanzadeev A, Kharlov Y, Kikola D, Kileng B, Kim DJ, Kim DS, Kim DW, Kim HN, Kim J, Kim JH, Kim JS, Kim M, Kim M, Kim SH, Kim S, Kim Y, Kirsch S, Kisel I, Kiselev S, Kisiel A, Klay JL, Klein J, Klein-Bösing C, Kliemant M, Klovning A, Kluge A, Knichel ML, Kniege S, Koch K, Kolevatov R, Kolojvari A, Kondratiev V, Kondratyeva N, Konevskih A, Kornaś E, Kour R, Kowalski M, Kox S, Kozlov K, Kral J, Králik I, Kramer F, Kraus I, Kravcáková A, Krawutschke T, Krivda M, Krumbhorn D, Krus M, Kryshen E, Krzewicki M, Kucheriaev Y, Kuhn C, Kuijer PG, Kumar L, Kumar N, Kupczak R, Kurashvili P, Kurepin A, Kurepin AN, Kuryakin A, Kushpil S, Kushpil V, Kutouski M, Kvaerno H, Kweon MJ, Kwon Y, La Rocca P, Lackner F, Ladrón de Guevara P, Lafage V, Lal C, Lara C, Larsen DT, Laurenti G, Lazzeroni C, Le Bornec Y, Le Bris N, Lee H, Lee KS, Lee SC, Lefèvre F, Lenhardt M, Leistam L, Lehnert J, Lenti V, León H, León Monzón I, León Vargas H, Lévai P, Li X, Li Y, Lietava R, Lindal S, Lindenstruth V, Lippmann C, Lisa MA, Liu L, Loginov V, Lohn S, Lopez X, López Noriega M, López-Ramírez R, López Torres E, Løvhøiden G, Lozea Feijo Soares A, Lu S, Lunardon M, Luparello G, Luquin L, Lutz JR, Ma K, Ma R, Madagodahettige-Don DM, Maevskaya A, Mager M, Mahapatra DP, Maire A, Makhlyueva I, Mal'kevich D, Malaev M, Malagalage KJ, Maldonado Cervantes I, Malek M, Malkiewicz T, Malzacher P, Mamonov A, Manceau L, Mangotra L, Manko V, Manso F, Manzari V, Mao Y, Mares J, Margagliotti GV, Margotti A, Marín A, Martashvili I, Martinengo P, Martínez Hernández MI, Martínez Davalos A, Martínez García G, Maruyama Y, Marzari Chiesa A, Masciocchi S, Masera M, Masetti M, Masoni A, Massacrier L, Mastromarco M, Mastroserio A, Matthews ZL, Matyja A, Mayani D, Mazza G, Mazzoni MA, Meddi F, Menchaca-Rocha A, Mendez Lorenzo P, Meoni M, Mercado Pérez J, Mereu P, Miake Y, Michalon A, Miftakhov N, Milano L, Milosevic J, Minafra F, Mischke A, Miśkowiec D, Mitu C, Mizoguchi K, Mlynarz J, Mohanty B, Molnar L, Mondal MM, Montaño Zetina L, Monteno M, Montes E, Morando M, Moretto S, Morsch A, Moukhanova T, Muccifora V, Mudnic E, Muhuri S, Müller H, Munhoz MG, Munoz J, Musa L, Musso A, Nandi BK, Nania R, Nappi E, Navach F, Navin S, Nayak TK, Nazarenko S, Nazarov G, Nedosekin A, Nendaz F, Newby J, Nianine A, Nicassio M, Nielsen BS, Nikolaev S, Nikolic V, Nikulin S, Nikulin V, Nilsen BS, Nilsson MS, Noferini F, Nomokonov P, Nooren G, Novitzky N, Nyatha A, Nygaard C, Nyiri A, Nystrand J, Ochirov A, Odyniec G, Oeschler H, Oinonen M, Okada K, Okada Y, Oldenburg M, Oleniacz J, Oppedisano C, Orsini F, Ortiz Velasquez A, Ortona G, Oskarsson A, Osmic F, Osterman L, Ostrowski P, Otterlund I, Otwinowski J, Ovrebekk G, Oyama K, Ozawa K, Pachmayer Y, Pachr M, Padilla F, Pagano P, Paić G, Painke F, Pajares C, Pal S, Pal SK, Palaha A, Palmeri A, Panse R, Papikyan V, Pappalardo GS, Park WJ, Pastircák B, Pastore C, Paticchio V, Pavlinov A, Pawlak T, Peitzmann T, Pepato A, Pereira H, Peressounko D, Pérez C, Perini D, Perrino D, Peryt W, Peschek J, Pesci A, Peskov V, Pestov Y, Peters AJ, Petrácek V, Petridis A, Petris M, Petrov P, Petrovici M, Petta C, Peyré J, Piano S, Piccotti A, Pikna M, Pillot P, Pinazza O, Pinsky L, Pitz N, Piuz F, Platt R, Płoskoń M, Pluta J, Pocheptsov T, Pochybova S, Podesta Lerma PLM, Poggio F, Poghosyan MG, Polák K, Polichtchouk B, Polozov P, Polyakov V, Pommeresch B, Pop A, Posa F, Pospísil V, Potukuchi B, Pouthas J, Prasad SK, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puddu G, Pujahari P, Pulvirenti A, Punin A, Punin V, Putis M, Putschke J, Quercigh E, Rachevski A, Rademakers A, Radomski S, Räihä TS, Rak J, Rakotozafindrabe A, Ramello L, Ramírez Reyes A, Rammler M, Raniwala R, Raniwala S, Räsänen SS, Rashevskaya I, Rath S, Read KF, Real JS, Redlich K, Renfordt R, Reolon AR, Reshetin A, Rettig F, Revol JP, Reygers K, Ricaud H, Riccati L, Ricci RA, Richter M, Riedler P, Riegler W, Riggi F, Rivetti A, Rodriguez Cahuantzi M, Røed K, Röhrich D, Román López S, Romita R, Ronchetti F, Rosinský P, Rosnet P, Rossegger S, Rossi A, Roukoutakis F, Rousseau S, Roy C, Roy P, Rubio-Montero AJ, Rui R, Rusanov I, Russo G, Ryabinkin E, Rybicki A, Sadovsky S, Safarík K, Sahoo R, Saini J, Saiz P, Sakata D, Salgado CA, Salgueiro Domingues da Silva R, Salur S, Samanta T, Sambyal S, Samsonov V, Sándor L, Sandoval A, Sano M, Sano S, Santo R, Santoro R, Sarkamo J, Saturnini P, Scapparone E, Scarlassara F, Scharenberg RP, Schiaua C, Schicker R, Schindler H, Schmidt C, Schmidt HR, Schossmaier K, Schreiner S, Schuchmann S, Schukraft J, Schutz Y, Schwarz K, Schweda K, Scioli G, Scomparin E, Scott PA, Segato G, Semenov D, Senyukov S, Seo J, Serci S, Serkin L, Serradilla E, Sevcenco A, Sgura I, Shabratova G, Shahoyan R, Sharkov G, Sharma N, Sharma S, Shigaki K, Shimomura M, Shtejer K, Sibiriak Y, Siciliano M, Sicking E, Siddi E, Siemiarczuk T, Silenzi A, Silvermyr D, Simili E, Simonetti G, Singaraju R, Singh R, Singhal V, Sinha BC, Sinha T, Sitar B, Sitta M, Skaali TB, Skjerdal K, Smakal R, Smirnov N, Snellings R, Snow H, Søgaard C, Soloviev A, Soltveit HK, Soltz R, Sommer W, Son CW, Son H, Song M, Soos C, Soramel F, Soyk D, Spyropoulou-Stassinaki M, Srivastava BK, Stachel J, Staley F, Stan E, Stefanek G, Stefanini G, Steinbeck T, Stenlund E, Steyn G, Stocco D, Stock R, Stolpovsky P, Strmen P, Suaide AAP, Subieta Vásquez MA, Sugitate T, Suire C, Sumbera M, Susa T, Swoboda D, Symons J, Szanto de Toledo A, Szarka I, Szostak A, Szuba M, Tadel M, Tagridis C, Takahara A, Takahashi J, Tanabe R, Tapia Takaki JD, Taureg H, Tauro A, Tavlet M, Tejeda Muñoz G, Telesca A, Terrevoli C, Thäder J, Tieulent R, Tlusty D, Toia A, Tolyhy T, Torcato de Matos C, Torii H, Torralba G, Toscano L, Tosello F, Tournaire A, Traczyk T, Tribedy P, Tröger G, Truesdale D, Trzaska WH, Tsiledakis G, Tsilis E, Tsuji T, Tumkin A, Turrisi R, Turvey A, Tveter TS, Tydesjö H, Tywoniuk K, Ulery J, Ullaland K, Uras A, Urbán J, Urciuoli GM, Usai GL, Vacchi A, Vala M, Valencia Palomo L, Vallero S, van der Kolk N, Vande Vyvre P, van Leeuwen M, Vannucci L, Vargas A, Varma R, Vasiliev A, Vassiliev I, Vasileiou M, Vechernin V, Venaruzzo M, Vercellin E, Vergara S, Vernet R, Verweij M, Vetlitskiy I, Vickovic L, Viesti G, Vikhlyantsev O, Vilakazi Z, Villalobos Baillie O, Vinogradov A, Vinogradov L, Vinogradov Y, Virgili T, Viyogi YP, Vodopianov A, Voloshin K, Voloshin S, Volpe G, von Haller B, Vranic D, Vrláková J, Vulpescu B, Wagner B, Wagner V, Wallet L, Wan R, Wang D, Wang Y, Wang Y, Watanabe K, Wen Q, Wessels J, Westerhoff U, Wiechula J, Wikne J, Wilk A, Wilk G, Williams MCS, Willis N, Windelband B, Xu C, Yang C, Yang H, Yasnopolskiy S, Yermia F, Yi J, Yin Z, Yokoyama H, Yoo IK, Yuan X, Yurevich V, Yushmanov I, Zabrodin E, Zagreev B, Zalite A, Zampolli C, Zanevsky Y, Zaporozhets S, Zarochentsev A, Závada P, Zbroszczyk H, Zelnicek P, Zenin A, Zepeda A, Zgura I, Zhalov M, Zhang X, Zhou D, Zhou S, Zhu J, Zichichi A, Zinchenko A, Zinovjev G, Zoccarato Y, Zychácek V, Zynovyev M. Midrapidity antiproton-to-proton ratio in pp collisons at sqrt[s]=0.9 and 7 TeV measured by the ALICE experiment. Phys Rev Lett 2010; 105:072002. [PMID: 20868032 DOI: 10.1103/physrevlett.105.072002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/29/2010] [Indexed: 05/29/2023]
Abstract
The ratio of the yields of antiprotons to protons in pp collisions has been measured by the ALICE experiment at sqrt[s]=0.9 and 7 TeV during the initial running periods of the Large Hadron Collider. The measurement covers the transverse momentum interval 0.45<p_{t}<1.05 GeV/c and rapidity |y|<0.5. The ratio is measured to be R_{|y|<0.5}=0.957±0.006(stat)±0.014(syst) at 0.9 TeV and R_{|y|<0.5}=0.991±0.005(stat)±0.014(syst) at 7 TeV and it is independent of both rapidity and transverse momentum. The results are consistent with the conventional model of baryon-number transport and set stringent limits on any additional contributions to baryon-number transfer over very large rapidity intervals in pp collisions.
Collapse
Affiliation(s)
- K Aamodt
- Department of Physics, University of Oslo, Oslo, Norway
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Narayanan BA, Kim HN, Chinnaiyan AM, Melamed J, Narayanan NK. Abstract 4032: Elevated level of let-7a and mir-30c microRNAs in human prostate cancer. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-4032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
MicroRNAs (miRNAs) are endogenously expressed non-coding RNAs that negatively regulate the expression of protein coding genes at the translational level. Evidence from recent studies suggests that cancer development is associated with deregulation of specific set of miRNAs that determines the cancer characteristics. Recently, miRNA profiling has been shown to identify cancer specific miRNA signatures that are specific to different cellular origin. However, the functional significance of specific miRNAs in prostate cancer developmental stages remains to be investigated. Further, identification and characterization of tumor derived miRNAs using advanced and reliable techniques may benefit early detection and prevention strategies. In this study, to identify potential miRNAs in human prostate cancer tissue specimens, we used 15 human prostate cancer tissue microarrays (TMAs) with 36 cores in each representing different stages of the cancer. We detected the expression of miRNA let-7a and mir-30c by performing locked nucleic acid-in-situ hybridization (LNA-ISH) (EXIQON, Vedbaek, Denmark). To obtain maximal sensitivity of miRNA expression signal, we used double (3′ and 5″) digoxigenin-labeled LNA probes (MiRCURY LNA) of 20uM each after optimizing with lower and higher dilutions. Oversaturation was avoided by reducing the temperature (30-35°C) and the time of exposure (24h). As a negative control the tissues were hybridized either with mismatch or no probe. We determined the expression level of the miRNAs in (a) precancerous single acinus or small group of acini and (b) in the regions of prostatic adenocarcinoma or high grade PIN. Our findings indicated abundant expression of both let-7a and mir-30c localized only in the nucleus of the cells in HGPIN, in contrary to that in the early PIN lesions, where let-7 and mir-30c miRNAs were localized both in the cytoplasm, as well as in the nucleus. Interestingly, not all the acini showed a positive staining for let-7, suggesting the possibility of down regulation of let-7 in the non-neoplastic regions. Finally, the difference in the expression of let-7a and mir-30c in the stroma vs. tumor acini were compared and quantified to predict their functional significance related to tumor proliferation. Although the findings on the expression of let-7a and mir-30c were consistent in more than 20% of the TMAs examined, we observed weak or no signal in several of the tumor acini (5%) suggesting a heterogeneous expression pattern. Overall, our findings suggest that examining the expression level of miRNAs in the nucleus vs. cytoplasm of tumor cells at different stages of prostate cancer is critical to determine the functional status of let-7a and mir30c. Most importantly, monitoring a shift in their expression pattern will provide significant opportunities to define diagnostically useful miRNA as biomarkers.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4032.
Collapse
Affiliation(s)
| | - Hye Na Kim
- 1New York Univ. School of Medicine, Tuxedo, NY
| | | | | | | |
Collapse
|
42
|
Kim HN, He F, Narayanan NK, Zavadil J, Wu XR, Narayanan B. Abstract 1475: Molecular mechanisms of “SNAIL” activation in invasive bladder cancer of p53/Rb double knockout mice exposed to chemical carcinogen BBN. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-1475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Epithelial-mesenchymal transition (EMT) plays a central role in empowering tumor cells to acquire invasive properties. It appears that EMT is not a random process but is highly regulated by transcription regulators. Of particular interests are the transcription repressors that inhibit the expression of cell-cell junction proteins, such as E-cadherin. Recent in vitro studies indicate that increased signaling of “Snail” the transcription repressor per se is sufficient to confer an invasive phenotype on otherwise non-invasive cells. Despite these recent advances, relatively little is known about the mechanisms of Snail activation in invasive bladder cancer. In this study, using p53 and Rb double knockout mice exposed the carcinogen BBN, we examined the expression levels of “Snail” and E-cadherin protein in bladder cancer tissues. Findings from both immunohistochemical and immunofluorescence staining revealed overexpression of Snail in the stromal as well as in the tumor regions. Although a complete loss of E-cadherin was not evident in all the tumors examined, most of the sections analyzed showed a moderate to weak expression of E-cadherin. This is consistent with the findings from Western blot analysis of the protein lysate from human bladder cancer cells with varying status of p53 and Rb. To explore the mechanism of Snail activation leading invasive bladder cancer, we transfected the human bladder cancer cells with siRNAs for Snail, p53 and Rb. Our findings were consistent with the in vivo studies, in that Western blot analysis revealed only a moderate inhibition of E-cadherin in p53 or Rb knockout cells. However, the Snail knockout cells showed less invasiveness (migration) compared to the control, and was associated with a significant inhibition of E-cadherin expression. To investigate further on the possible role of TGFβ on Snail activation, we treated the bladder cancer cells with TGFβ for 12h and examined the effect on Smad 4 and 7, Snail and E-cadherin expression. Activation of Snail was associated the expression of vimentin, a typical marker of mesenchymal cells, and cytokeratins of epithelial cells suggesting TGFβ mediated Snail activation. Finally, we extended our analysis to determine the role of noncoding microRNAs that act as post-transcriptional repressors. To this end we performed microRNA profiling of J82 and HT1376 bladder cancer cells using human miRNA arrays. Findings on differential expression of potential microRNA network involved in the regulation of TGFβ, Snail and E-cadherin expression associated with urothelial tumor plasticity are discussed. Overall findings from these studies suggest possible mechanism(s) of Snail activation and E-cadherin regulation in invasive bladder cancer for the first time and may pave the way for novel therapeutic approaches.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1475.
Collapse
Affiliation(s)
- Hye Na Kim
- 1New York University School of Medicine, Department of Environmental Medicine, Tuxedo, NY
| | - Feng He
- 2New York University School of Medicine, Department of Urology, New York, NY
| | - Narayanan K. Narayanan
- 1New York University School of Medicine, Department of Environmental Medicine, Tuxedo, NY
| | - Jiri Zavadil
- 3New York University School of Medicine, Cancer Institute, New York, NY
| | - Xue-Ru Wu
- 2New York University School of Medicine, Department of Urology, New York, NY
| | - Bhagavathi Narayanan
- 1New York University School of Medicine, Department of Environmental Medicine, Tuxedo, NY
| |
Collapse
|
43
|
Kim HN, Harrington RD, Crane HM, Dhanireddy S, Dellit TH, Spach DH. Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS 2009; 20:595-600. [PMID: 19710329 DOI: 10.1258/ijsa.2009.009126] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Immunization with hepatitis B (HBV) vaccine is recommended for all HIV-infected individuals without immunity to HBV. This patient population, however, has relatively poor HBV vaccine responses. Factors associated with this impaired HBV vaccine response in HIV-infected individuals may include older age, uncontrolled HIV replication, and low nadir CD4 cell count. Postvaccination testing for HBV surface antibody is recommended and vaccine non-responders should undergo repeat immunization with a full series. The benefit of double dosage, the appropriate strategy for HIV-infected patients with isolated HBV core antibody and the timing and number of vaccinations in persons with advanced immunosuppression on highly active antiretroviral therapy remain controversial areas.
Collapse
Affiliation(s)
- H N Kim
- Division of Allergy & Infectious Diseases, Department of Medicine, University of Washington, Harborview Medical Center, Seattle, WA, USA.
| | | | | | | | | | | |
Collapse
|
44
|
Haznedaroglu BZ, Kim HN, Bradford SA, Walker SL. Relative transport behavior of Escherichia coli O157:H7 and Salmonella enterica serovar pullorum in packed bed column systems: influence of solution chemistry and cell concentration. Environ Sci Technol 2009; 43:1838-1844. [PMID: 19368180 DOI: 10.1021/es802531k] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
The influence of solution chemistry and cell concentration on bacterial transport has been examined using Salmonella pullorum SA1685 and Escherichia coli O157:H7. A column was employed to determine the transport behavior and deposition kinetics with aquifer sand over a range of ionic strengths and cell concentrations. O157:H7 was found to be more adhesive than SA1685, with calculated deposition rate coefficients higher than those of SA1685. Comprehensive cell surface characterization techniques including size, surface charge density, extracellular polymeric substance content, electrophoretic mobility, and hydrophobicity analyses were conducted to explain observed transporttrends. The pathogens' size and hydrophobicity were not significantly different, whereas they varied in acidity, for which O157:H7 had 19 times higher surface charge density than SA1685. Electrophoretic mobilities, in general agreement with titration analysis and column experiments, revealed SA1685 to be more negative than O157:H7. This combination of column and characterization experiments indicates that SA1685 can be transported to a greater extent than O157:H7 in groundwater environments. This study is the first comprehensive work comparing the transport behavior of two important pathogens in aquifer systems.
Collapse
Affiliation(s)
- B Z Haznedaroglu
- Department of Chemical & Environmental Engineering, University of California, Riverside, California 92521, USA
| | | | | | | |
Collapse
|
45
|
Abstract
BACKGROUND AND PURPOSE Cornelia de Lange syndrome is a rare developmental malformation syndrome with a high prevalence of hearing impairment. The purposes of this study were to describe the characteristic temporal bone CT findings in patients with Cornelia de Lange syndrome and to correlate audiometric data with radiologic findings in these patients. MATERIALS AND METHODS Ten children (6 girls and 4 boys; mean age, 42.0 months) who were clinically diagnosed with Cornelia de Lange syndrome (classic, n = 5; mild form, n = 5) were enrolled. Temporal bone CT was prospectively performed, and 32 aspects of each temporal bone CT were analyzed, 21 by direct measurement and 11 by visual inspection. Twenty age-matched children (n = 20 ears) with normal temporal bone CT scans served as a control group. Audiologic tests were also performed on all patients. RESULTS Characteristic temporal bone CT findings of Cornelia de Lange syndrome were external auditory canal stenosis, soft-tissue opacification of the hypoplastic tympanomastoid cavity, dysmorphic ossicle, hypoplastic cochlea, and dysplastic vestibule, all of which were more prevalent in patients with the classic form of the disease than in those with the mild form. Children who had more severe structural abnormalities on temporal bone CT had worse hearing levels compared with those without structural abnormalities. CONCLUSION Temporal bone CT scans in Cornelia de Lange syndrome could document combined structural abnormalities of the external, middle, and inner ear, which were one of the characteristic clinical manifestations; CT abnormalities were well correlated with the audiometric data.
Collapse
Affiliation(s)
- J Kim
- Department of Radiology, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Korea
| | | | | | | | | |
Collapse
|
46
|
Shigenaga Y, Moritani M, Oh SJ, Park KP, Paik SK, Bae JY, Kim HN, Ma SK, Park CW, Yoshida A, Ottersen OP, Bae YC. The distribution of inhibitory and excitatory synapses on single, reconstructed jaw-opening motoneurons in the cat. Neuroscience 2005; 133:507-18. [PMID: 15878646 DOI: 10.1016/j.neuroscience.2005.02.022] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2005] [Revised: 02/03/2005] [Accepted: 02/12/2005] [Indexed: 11/21/2022]
Abstract
In a previous study, we reported that the distribution of inhibitory input, in contrast to excitatory input, decreased somatofugally along dendrites of cat jaw-closing alpha-motoneurons [J Comp Neurol 414 (1999) 454]. The present study examined the distribution of GABA, glycine, and glutamate immunopositive boutons covering horseradish peroxidase-labeled cat jaw-opening motoneurons. The motoneurons were divided into four compartments: the soma, and primary, intermediate, and distal dendrites. Ninety-seven percent of the total number of studied boutons had immunoreactivity for at least one of the three amino acids. The proportion of boutons immunoreactive for GABA and/or glycine was lower than the proportion of boutons immunoreactive for glutamate. Boutons immunoreactive to glycine alone were more numerous than boutons double-labeled for GABA and glycine, which, in turn, occurred more frequently than boutons immunoreactive to GABA alone. The percentage synaptic covering (proportion of membrane covered by synaptic boutons) of the putatively excitatory (glutamate containing) and putatively inhibitory (GABA and/or glycine containing) boutons decreased somatofugally along the dendrites. Such systematic variations were not seen in the packing density (number of boutons per 100 microm(2)); the packing density showed a distinct drop between the soma and primary dendrites but did not differ significantly among the three dendritic compartments. Overall, the packing density was slightly higher for the putatively excitatory boutons than for the inhibitory ones. When taken together with previous analyses of jaw-closing alpha-motoneurons the present data on jaw-opening alpha-motoneurons indicate that the two types of neuron differ in regard to the nature of synaptic integration in the dendritic tree.
Collapse
Affiliation(s)
- Y Shigenaga
- Department of Oral Anatomy and Neurobiology, School of Dentistry, Kyungpook National University, Jung-Gu, Daegu 700-412, Korea.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Chung IJ, Lee JJ, Nam CE, Kim HN, Kim YK, Park MR, Cho SH, Kim HJ. Increased inducible nitric oxide synthase expression and nitric oxide concentration in patients with aplastic anemia. Ann Hematol 2003; 82:104-108. [PMID: 12601489 DOI: 10.1007/s00277-002-0602-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2002] [Accepted: 12/08/2002] [Indexed: 11/24/2022]
Abstract
Nitric oxide (NO) is a biological mediator that is synthesized from L-arginine by the nitric oxide synthase (NOS) family. We investigated the expression of iNOS in bone marrow (BM) mononuclear cells (MNCs) using a reverse transcriptase polymerase chain reaction (RT-PCR) assay and the concentration of NO from BM serum by measuring the metabolite NO(2)(-) in 13 patients with aplastic anemia (AA) compared with 10 normal controls who were donors for allogeneic bone marrow transplantation (BMT). All samples of BM MNCs in patients with AA expressed iNOS mRNA, but iNOS was not expressed in patients who were treated successfully with allogeneic BMT. Normal control samples and samples from leukemia patients who had bone marrow aplasia after chemotherapy did not show significant iNOS expression. When we measured the density of bands for both iNOS and beta(2)-microglobin expressed as the iNOS/beta(2)-microglobin density ratio, there was a significant difference in the ratio between AA and normal controls (0.88+/-0.15 vs 0.26+/-0.05, P<0.001). The BM serum NO(2)(-) concentration in the patients with AA was significantly higher than that of normal controls (88.1+/-32.8 microM vs 48.8+/-8.6 microM, P=0.002). In addition, there was a significant correlation between the NO(2)(-) concentration and the calculated iNOS/beta(2)-microglobin density ratio (r=0.567, P=0.01). These findings suggest that upregulation of iNOS expression for local NO production may contribute in part to the pathogenesis of AA.
Collapse
Affiliation(s)
- I-J Chung
- Department of Internal Medicine, Chonnam National University Medical School, 8 Hak-Dong, 501-757, Dong-Ku, Gwangju, South Korea
- Genome Research Center for Hematopoietic Diseases, Chonnam National University Hospital, Gwangju, South Korea
| | - J-J Lee
- Department of Internal Medicine, Chonnam National University Medical School, 8 Hak-Dong, 501-757, Dong-Ku, Gwangju, South Korea
- Genome Research Center for Hematopoietic Diseases, Chonnam National University Hospital, Gwangju, South Korea
| | - C-E Nam
- Genome Research Center for Hematopoietic Diseases, Chonnam National University Hospital, Gwangju, South Korea
| | - H N Kim
- Genome Research Center for Hematopoietic Diseases, Chonnam National University Hospital, Gwangju, South Korea
| | - Y-K Kim
- Department of Internal Medicine, Chonnam National University Medical School, 8 Hak-Dong, 501-757, Dong-Ku, Gwangju, South Korea
| | - M-R Park
- Department of Internal Medicine, Chonnam National University Medical School, 8 Hak-Dong, 501-757, Dong-Ku, Gwangju, South Korea
| | - S-H Cho
- Department of Internal Medicine, Chonnam National University Medical School, 8 Hak-Dong, 501-757, Dong-Ku, Gwangju, South Korea
| | - H-J Kim
- Department of Internal Medicine, Chonnam National University Medical School, 8 Hak-Dong, 501-757, Dong-Ku, Gwangju, South Korea.
- Genome Research Center for Hematopoietic Diseases, Chonnam National University Hospital, Gwangju, South Korea.
| |
Collapse
|
48
|
Lee SH, Kim CS, Kim HN, Kim LS, Huh MJ, Cho TH, Shim YJ. Satisfaction with the cochlear implant of pre- and postlingually deaf adults. Adv Otorhinolaryngol 2002; 57:273-6. [PMID: 11892166 DOI: 10.1159/000059121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- S H Lee
- Department of Otorhinolaryngology, College of Medicine, Kyungpook National University, Taegu, Korea.
| | | | | | | | | | | | | |
Collapse
|
49
|
Lee SH, Kim CS, Kim HN, Kim LS, Cho TH. Sound and speech recognition ability in Korean cochlear implantees, prelingually deaf children. Adv Otorhinolaryngol 2002; 57:343-6. [PMID: 11892185 DOI: 10.1159/000059208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- S H Lee
- Department of Otorhinolaryngology, College of Medicine, Kyungpook National University, Taegu, Korea.
| | | | | | | | | |
Collapse
|
50
|
Affiliation(s)
- H N Kim
- Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Korea.
| | | | | | | |
Collapse
|